

## Citations and Reference Literature: Folic Acid

### Citations

1. Pfeiffer CM, Caudill SP, Gunter EW et al. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. *Am J Clin Nutr* 2005;82:442-450.
2. Canfield MA, Collins JS, Botto LD et al. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. *Birth Defects Res A Clin Mol Teratol* 2005;73:679-689.
3. Stark KD, Pawlosky RJ, Bebilo S et al. Status of plasma folate after folic acid fortification of the food supply in pregnant African American women and the influences of diet, smoking, and alcohol consumption. *Am J Clin Nutr* 2005;81:669-677.
4. Brent RL, Oakley GP Jr. The Food and Drug Administration must require the addition of more folic acid in "enriched" flour and other grains. *Pediatrics* 2005;116:753-755.
5. Brent RL, Oakley GP Jr. Triumph and/or tragedy: the present Food and Drug Administration program of enriching grains with folic acid. *Pediatrics* 2006;117:930-932.
6. Martinez ME, Giovannucci E, Jiang R et al. Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. *Int J Cancer* 2006;119:1440-1446.
7. Bentley TG, Willett WC, Weinstein MC, Kuntz KM. Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. *Am J Public Health* 2006;96:2040-2047.
8. Sherwood KL, Houghton LA, Tarasuk V, O'Connor DL. One-third of pregnant and lactating women may not be meeting their folate requirements from diet alone based on mandated levels of folic acid fortification. *J Nutr* 2006;136:2820-2826.
9. Ricciuto LE, Tarasuk VS. An examination of income-related disparities in the nutritional quality of food selections among Canadian households from 1986-2001. *Soc Sci Med* 2007;64:186-198.
10. Lawrence JM, Watkins ML, Chiu V et al. Do racial and ethnic differences in serum folate values exist after food fortification with folic acid? *Am J Obstet Gynecol* 2006;194:520-526.
11. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. *Pediatrics* 2006;117:803-813.
12. Devlin AM, Clarke R, Birks J et al. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. *Am J Clin Nutr* 2006;83:708-713.
13. MetafolinTM scientific review. Darmstadt, Germany: Merck KGaA; 2004.
14. Metafolin®: about the product. Product brochure. Darmstadt, Germany: Merck KGaA; 2004.
15. Van der Griend R, Haas FJ, Biesma DH et al. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives. *Atherosclerosis* 1999;143:177-183.
16. Morris MC, Evans DA, Bienias JL et al. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. *Arch Neurol* 2005;62:641-645.
17. Tucker KL, Qiao N, Scott T et al. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. *Am J Clin Nutr* 2005;82:627-635.
18. Sazawal S, Black RE, Ramsan M et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. *Lancet* 2006;367:133-152.
19. Haggarty P, McCallum H, McBain H et al. Effect of B vitamins and genetics on success of in-vitro fertilisation: prospective cohort study. *Lancet* 2006;367:1513-1519.
20. Eussen SJ, de Groot LC, Clarke R et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. *Arch Intern Med* 2005;165:1167-1172.
21. Bottiglieri T, Díaz-Arrastia R. Hyperhomocysteinemia and cognitive function: more than just a casual link? *Am J Clin Nutr* 2005;82:493-494.
22. Ramos MI, Allen LH, Mungas DM et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. *Am J Clin Nutr* 2005;82:1346-1352.
23. Ravaglia G, Forti P, Maioli F et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. *Am J Clin Nutr* 2005;82:636-643.
24. Ravaglia G, Forti P, Maioli F et al. Folate, but not homocysteine, predicts the risk of fracture in elderly persons. *J Gerontol A Biol Sci Med Sci* 2005;60:1458-1462.
25. Gjesdal CG, Vollset SE, Ueland PM et al. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. *Arch Intern Med* 2006;166:88-94.
26. Durga J, van Boxtel MP, Schouten EG et al. Folate and the methylenetetrahydrofolate reductase 677C→T mutation correlate with cognitive performance. *Neurobiol Aging* 2006;27:334-343.

## Citations and Reference Literature: Folic Acid

27. Lin P-T, Lee B-J, Chang H-H et al. Low-dose folic acid supplementation reduces homocysteine concentration in hyperhomocysteinemic coronary artery disease patients. *Nutr Res* 2006;26:460-466.
- 27a. Spence JD, Bang H, Chambliss LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention Trial: an efficacy analysis. *Stroke* 2005;36(11):2404-2409.
28. Bønaa KH. NORVIT: Norwegian Study of Homocysteine Lowering with B Vitamins in Myocardial Infarction. European Society of Cardiology 2005 Congress. Stockholm, 2005.
29. Bønaa KH, Njølstad I, Ueland PM et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* 2006;354:1578-1588.
30. Lonn E, Yusuf S, Arnold JM et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006;354:1567-1577.
31. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *BMJ* 2006;333:1114-1117.
32. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA* 2006;296:2720-2726.
33. Moat SJ, Madhavan A, Taylor SY et al. High- but not low-dose folic acid improves endothelial function in coronary artery disease. *Eur J Clin Invest* 2006;36:850-859.
34. Moat SJ, Clarke ZL, Madhavan AK et al. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. *Eur J Pharmacol* 2006;530:250-258.
35. Durga J, Verhoef P, Anteunis LJC et al. Effects of folic acid supplementation on hearing in older adults: a randomized, controlled trial. *Ann Intern Med* 2007;146:1-9.
36. Buist RA. Drug-nutrient interactions: an overview. *Int Clin Nutr Rev* 1984;4:114.
37. Alter HJ, Zvaifler NJ, Rath CE. Interrelationship of rheumatoid arthritis, folic acid, and aspirin. *Blood* 1971;38:405-416.
38. Lawrence VA, Loewenstein JE, Eichner ER. Aspirin and folate binding: in vivo and in vitro studies of serum binding and urinary excretion of endogenous folate. *J Lab Clin Med* 1984;103:944-948.
39. Baggott JE, Morgan SL, Ha T et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. *Biochem J* 1992;282(pt 1):197-202.
40. Benn A, Swan CH, Cooke WT et al. Effect of intraluminal pH on the absorption of pteroylmonoglutamic acid. *BMJ* 1971;1:148-150.
41. Russell RM, Golner BB, Krasinski SD et al. Effect of antacid and H<sub>2</sub> receptor antagonists on the intestinal absorption of folic acid. *J Lab Clin Med* 1988;112:458-463.
42. Stumm W, Morgan JJ. Aquatic Chemistry: an Introduction Emphasizing Chemical Equilibria in Natural Waters. New York: Wiley; 1981.
- 42a. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. *Ann Pharmacother* 2002;36:812-816.
43. Berg MJ, Stumbo PJ, Chenard CA et al. Folic acid improves phenytoin pharmacokinetics. *J Am Diet Assoc* 1995;95:352-356.
44. Lewis DP, Van Dyke DC, Willhite LA et al. Phenytoin-folic acid interaction. *Ann Pharmacother* 1995;29:726-735.
45. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. *J Neurol Sci* 1997;145:109-112.
46. Apeland T, Mansoor MA, Pentieva K et al. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. *Clin Chem* 2003;49:1005-1008.
47. Reynolds EH. Mental effects of anticonvulsants, and folic acid metabolism. *Brain* 1968;91:197-214.
48. Hendel J, Dam M, Gram L et al. The effects of carbamazepine and valproate on folate metabolism in man. *Acta Neurol Scand* 1984;69:226-231.
49. Isojarvi JI, Pakarinen AJ, Myllyla VV. Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy. *Seizure* 1997;6:207-211.
50. Chang T, Savory A, Glazko AJ. A new metabolite of 5,5-diphenylhydantoin (Dilantin). *Biochem Biophys Res Commun* 1970;38:444-449.
51. LaJoie J, Moshe SL. Effects of seizures and their treatment on fetal brain. *Epilepsia* 2004;45 Suppl 8:48-52.
52. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. *Epilepsia* 1996;37 Suppl 6:S34-44.
53. Jensen PK, Gram L, Schmutz M. Oxcarbazepine. *Epilepsy Res Suppl* 1991;3:135-140.
54. Hoffbrand AV, Necheles TF. Mechanism of folate deficiency in patients receiving phenytoin. *Lancet* 1968;2:528-530.

## Citations and Reference Literature: Folic Acid

55. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes. Part I. Antiepileptic drugs, contraceptives, smoking, and folate. *Ann Pharmacother* 1998;32:802-817.
56. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. *N Engl J Med* 2001;344:1132-1138.
57. Wyszynski DF, Nambisan M, Surve T et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. *Neurology* 2005;64:961-965.
58. Vinten J, Adab N, Kini U et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. *Neurology* 2005;64:949-954.
59. Ono H, Sakamoto A, Eguchi T et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. *Metabolism* 1997;46:959-962.
60. Schwaninger M, Ringleb P, Winter R et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. *Epilepsia* 1999;40:345-350.
61. Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. *Epilepsy Res* 2001;47:27-35.
62. Reynolds EH, Mattson RH, Gallagher BB. Relationships between serum and cerebrospinal fluid anticonvulsant drug and folic acid concentrations in epileptic patients. *Neurology* 1972;22:841-844.
63. Martinez Figueroa A, Johnson RH, Lambie DG, Shakir RA. The role of folate deficiency in the development of peripheral neuropathy caused by anticonvulsants. *J Neurol Sci* 1980;48:315-323.
64. Dastur DK, Dave UP. Effect of prolonged anticonvulsant medication in epileptic patients: serum lipids, vitamins B6, B12, and folic acid, proteins, and fine structure of liver. *Epilepsia* 1987;28:147-159.
65. Dansky LV, Andermann E, Rosenblatt D et al. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. *Ann Neurol* 1987;21:176-182.
66. Apeland T, Mansoor MA, Strandjord RE et al. Folate, homocysteine and methionine loading in patients on carbamazepine. *Acta Neurol Scand* 2001;103:294-299.
67. Karabiber H, Sonmezgoz E, Ozerol E et al. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. *Brain Dev* 2003;25:113-115.
68. Reynolds EH, Chanarin I, Milner G, Matthews DM. Anticonvulsant therapy, folic acid and vitamin B12 metabolism and mental symptoms. *Epilepsia* 1966;7:261-270.
69. Goggin T, Gough H, Bissessar A et al. A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy. *Q J Med* 1987;65:911-919.
70. James GK, Jones MW, Pudek MR. Homocyst(e)ine levels in patients on phenytoin therapy. *Clin Biochem* 1997;30:647-649.
71. Apeland T, Mansoor MA, Strandjord RE, Kristensen O. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. *Acta Neurol Scand* 2000;101:217-223.
72. Verrotti A, Pascarella R, Trotta D et al. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. *Epilepsy Res* 2000;41:253-257.
73. Yoo JH, Hong SB. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. *Metabolism* 1999;48:1047-1051.
74. Dean JC, Moore SJ, Osborne A et al. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. *Clin Genet* 1999;56:216-220.
75. Samren EB, van Duijn CM, Koch S et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. *Epilepsia* 1997;38:981-990.
76. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000;343:1608-1614.
77. Fonager K, Larsen H, Pedersen L, Sorensen HT. Birth outcomes in women exposed to anticonvulsant drugs. *Acta Neurol Scand* 2000;101:289-294.
78. Hvas CL, Henriksen TB, Ostergaard JR, Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. *BJOG* 2000;107:896-902.
79. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol* 2001;153:961-968.
80. Hansen DK. The embryotoxicity of phenytoin: an update on possible mechanisms. *Proc Soc Exp Biol Med* 1991;197:361-368.
81. Elmazar MM, Nau H. Ethanol potentiates valproic acid-induced neural tube defects (NTDs) in mice due to toxicokinetic interactions. *Reprod Toxicol* 1995;9:427-433.
82. Artama M, Auvinen A, Raudaskoski T et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. *Neurology* 2005;64:1874-1878.

## Citations and Reference Literature: Folic Acid

83. Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. *Epilepsy Res* 1999;33:145-158.
84. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. *Neurology* 2003;60:575-579.
85. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. *Clin Pharmacokinet* 1990;18:472-484.
86. Crawford P, Chadwick DJ, Martin C et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. *Br J Clin Pharmacol* 1990;30:892-896.
87. Shane-McWhorter L, Cerveny JD, MacFarlane LL, Osborn C. Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy. *Pharmacotherapy* 1998;18:1360-1364.
88. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. *Drugs* 1999;57:535-544.
89. Palmieri C, Canger R. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? *CNS Drugs* 2002;16:755-764.
90. Reynolds EH. Effects of folic acid on the mental state and fit-frequency of drug-treated epileptic patients. *Lancet* 1967;1:1086-1088.
91. Baylis EM, Crowley JM, Preece JM et al. Influence of folic acid on blood-phenytoin levels. *Lancet* 1971;1:62-64.
92. Gibberd FB, Nicholls A, Wright MG. The influence of folic acid on the frequency of epileptic attacks. *Eur J Clin Pharmacol* 1981;19:57-60.
93. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. *Eur J Obstet Gynecol Reprod Biol* 1984;18:211-216.
94. Eros E, Geher P, Gomor B, Czeizel AE. Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy). *Eur J Obstet Gynecol Reprod Biol* 1998;80:75-78.
95. Hiilesmaa VK, Teramo K, Granstrom ML, Bardy AH. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. *Br Med J (Clin Res Ed)* 1983;287:577-579.
96. Pack AR, Thomson ME. Effects of topical and systemic folic acid supplementation on gingivitis in pregnancy. *J Clin Periodontol* 1980;7:402-414.
97. Thomson ME, Pack AR. Effects of extended systemic and topical folate supplementation on gingivitis of pregnancy. *J Clin Periodontol* 1982;9:275-280.
98. Pack AR. Effects of folate mouthwash on experimental gingivitis in man. *J Clin Periodontol* 1986;13:671-676.
99. Drew HJ, Vogel RI, Molofsky W et al. Effect of folate on phenytoin hyperplasia. *J Clin Periodontol* 1987;14:350-356.
100. Francetti L, Maggiore E, Marchesi A et al. [Oral hygiene in subjects treated with diphenylhydantoin: effects of a professional program]. *Prev Assist Dent* 1991;17:40-43.
101. Brown RS, Di Stanislao PT, Beaver WT, Bottomley WK. The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia: a double-blind, randomized, placebo-controlled, parallel study. *Oral Surg Oral Med Oral Pathol* 1991;71:565-568.
102. Bell GS, Nashef L, Kendall S et al. Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. *Epilepsy Res* 2002;52:139-146.
103. Brent RL, Oakley GP Jr. The folate debate. *Pediatrics* 2006;117:1418-1419.
104. Cuskelly GJ, McNulty H, Scott JM. Fortification with low amounts of folic acid makes a significant difference in folate status in young women: implications for the prevention of neural tube defects. *Am J Clin Nutr* 1999;70:234-239.
105. Botto LD, Lisi A, Robert-Gnansia E et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? *BMJ* 2005;330:571.
106. Lucock M, Yates Z. Folic acid: vitamin and panacea or genetic time bomb? *Nat Rev Genet* 2005;6:235-240.
107. Frenkel EP, McCall MS, Sheehan RG. Cerebrospinal fluid folate, and vitamin B12 in anticonvulsant-induced megaloblastosis. *J Lab Clin Med* 1973;81:105-115.
108. Melamed E, Reches A, Hershko C. Reversible central nervous system dysfunction in folate deficiency. *J Neurol Sci* 1975;25:93-98.
109. Reynolds EH. Neurological aspects of folate and vitamin B12 metabolism. *Clin Haematol* 1976;5:661-696.
110. Girdwood RH. Drug-induced anaemias. *Drugs* 1976;11:394-404.
111. Weber TH, Knuutila S, Tammisto P, Tontti K. Long-term of phenytoin: effects on whole blood and red cell folate and haematological parameters. *Scand J Haematol* 1977;18:81-85.
112. Scott JM, Weir DG. Drug-induced megaloblastic change. *Clin Haematol* 1980;9:587-606.
113. Rivey MP, Schottelius DD, Berg MJ. Phenytoin-folic acid: a review. *Drug Intell Clin Pharm* 1984;18:292-301.
114. Lambie DG, Johnson RH. Drugs and folate metabolism. *Drugs* 1985;30:145-155.
115. Shalev O, Gilon D, Nubani NH. Masked phenytoin-induced megaloblastic anemia in beta-thalassemia minor. *Acta Haematol* 1987;77:186-187.

## Citations and Reference Literature: Folic Acid

116. Taliani U, Camellini A, Bernardi P et al. [A clinical case of severe megaloblastic anemia during treatment with primidone]. *Acta Biomed Ateneo Parmense* 1989;60:245-248.
117. Ravakhah K, West BC. Case report: subacute combined degeneration of the spinal cord from folate deficiency. *Am J Med Sci* 1995;310:214-216.
118. Guidolin L, Vignoli A, Canger R. Worsening in seizure frequency and severity in relation to folic acid administration. *Eur J Neurol* 1998;5:301-303.
119. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid–responsive neonatal seizures. *J Child Neurol* 1999;14:529-532.
120. Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. *Seizure* 1999;8:253-254.
121. Duncan S, Mercho S, Lopes-Cendes I et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. *Epilepsia* 2001;42:750-753.
122. Beardsley GP, Moroson BA, Taylor EC, Moran RG. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. *J Biol Chem* 1989;264:328-333.
123. Taylor EC, Harrington PJ, Fletcher SR et al. Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydraminopterin. *J Med Chem* 1985;28:914-921.
124. Taylor EC. Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents. *Adv Exp Med Biol* 1993;338:387-408.
125. Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. *Eur J Cancer* 2001;37:2310-2323.
126. Synold TW, Newman EM, Carroll M et al. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. *Clin Cancer Res* 1998;4:2349-2355.
127. Jackson RC. Biological effects of folic acid antagonists with antineoplastic activity. *Pharmacol Ther* 1984;25:61-82.
128. Norman P. Pemetrexed disodium (Eli Lilly). *Curr Opin Investig Drugs* 2001;2:1611-1622.
129. O'Shaughnessy JA. Pemetrexed: an active new agent for breast cancer. *Semin Oncol* 2002;29:57-62.
130. Adjei AA. Pharmacology and mechanism of action of pemetrexed. *Clin Lung Cancer* 2004;5 Suppl 2:S51-S55.
131. Adjei AA. Pemetrexed (Alimta), a novel multitargeted antineoplastic agent. *Clin Cancer Res* 2004;10:4276s-4280s.
132. Calvert AH. Biochemical pharmacology of pemetrexed. *Oncology (Huntingt)* 2004;18:13-17.
133. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. *Arthritis Rheum* 1988;31:906-908.
134. Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. *J Rheumatol* 1988;15:1078-1080.
135. Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. *J Rheumatol* 1990;17:1158-1161.
136. Morgan SL, Baggott JE, Vaughn WH et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 1990;33:9-18.
137. Joyce DA, Will RK, Hoffman DM et al. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. *Ann Rheum Dis* 1991;50:913-914.
138. Morgan SL, Baggott JE, Vaughn WH et al. 5 mg or 50 mg/week dose of folic acid supplementation does not alter the efficacy of methotrexate-treated rheumatoid arthritis patients (abstract). *Arthritis Rheum* 1993;36:S79.
139. Shiroky JB, Neville C, Esdaile JM et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 1993;36:795-803.
140. Weinblatt ME, Maier AL, Coblyn JS. Low-dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8-week randomized placebo-controlled trial. *J Rheumatol* 1993;20:950-952.
141. Sessa C, de Jong J, D'Incalci M et al. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. *Clin Cancer Res* 1996;2:1123-1127.
142. Tomudex®. raltitrexed disodium. Mississauga, Ontario: AstraZeneca; 1998.
143. Leeb BF, Witzmann G, Ogris E et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. *Clin Exp Rheumatol* 1995;13:459-463.
144. Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate. *Rheum Dis Clin North Am* 1997;23:969-980.
145. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. *J Rheumatol* 1997;24:2230-2232.
146. Alarcon GS, Morgan SL. Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate: comment on the guidelines for monitoring drug therapy. *Arthritis Rheum* 1997;40:391; author reply 391-392.

## Citations and Reference Literature: Folic Acid

147. Van Ede AE, Laan RF, Blom HJ et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. *Semin Arthritis Rheum* 1998;27:277-292.
148. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low-dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. *J Rheumatol* 1998;25:441-446.
149. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. *J Am Acad Dermatol* 1993;28:466-469.
150. Suzuki Y, Uehara R, Tajima C et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate: risk factors and response to folic acid. *Scand J Rheumatol* 1999;28:273-281.
151. Griffith SM, Fisher J, Clarke S et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? *Rheumatology (Oxford)* 2000;39:1102-1109.
152. Van den Berg PB, Reicher A, de Jong-van den Berg LTW. Concomitant use of folic acid prolongs duration of MTX-therapy in the treatment of RA. *Pharmacopidemiol Drug Saf* 2000;9 Suppl:S16-S17.
153. Van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2001;44:1515-1524.
154. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. *Ann Rheum Dis* 2003;62:423-426.
155. Khanna D, Park GS, Paulus HE et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. *Arthritis Rheum* 2005;52:3030-3038.
156. Kirby B, Lyon CC, Griffiths CE, Chalmers RJ. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. *Clin Exp Dermatol* 2000;25:265-268.
157. Kager L, Cheok M, Yang W et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. *J Clin Invest* 2005;115:110-117.
158. Toffoli G, Veronesi A, Boiocchi M, Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). *Ann Oncol* 2000;11:373-374.
159. Ueland PM, Hustad S, Schneede J et al. Biological and clinical implications of the MTHFR C677T polymorphism. *Trends Pharmacol Sci* 2001;22:195-201.
160. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. *Blood* 2001;98:231-234.
161. Chiusolo P, Reddicono G, Casorelli I et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. *Ann Oncol* 2002;13:1915-1918.
162. Laverdiere C, Chiasson S, Costea I et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. *Blood* 2002;100:3832-3834.
163. Taub JW, Matherly LH, Ravindranath Y et al. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. *Leukemia* 2002;16:764-765.
164. Toffoli G, Russo A, Innocenti F et al. Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. *Int J Cancer* 2003;103:294-299.
165. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. *Ann Rheum Dis* 2005;64:1180-1185.
166. Ettinger DS. Pemetrexed (Alimta): a new antifolate for non-small-cell lung cancer. *Clin Lung Cancer* 2002;3 Suppl 1:S22-S25.
167. Budde LS, Hanna NH. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma. *Expert Rev Anticancer Ther* 2004;4:361-368.
168. Suwanrusme H, Meyer ML, Green MR. Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma. *Clin Lung Cancer* 2004;5 Suppl 2:S56-S60.
169. Bunn P Jr. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. *Oncology (Huntingt)* 2004;18:5-11.
170. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636-2644.
171. Matsui MS, Rozovski SJ. Drug-nutrient interaction. *Clin Ther* 1982;4:423-440.
172. Werbach MR. Foundations of Nutritional Medicine. Tarzana, Calif: Third Line Press; 1997.

## Citations and Reference Literature: Folic Acid

173. Cardiovascular Drugs, antihyperlipidemic agents, bile acid sequestrants. In: Threlkeld DS, ed. Facts and Comparisons Drug Information. St Louis: Facts and Comparisons; February 1999:171L.
174. Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. *Drugs* 2002;62:605-616.
175. Leonard JP, Desager JP, Beckers C, Harvengt C. In vitro binding of various biological substances by two hypocholesterolaemic resins: cholestyramine and colestipol. *Arzneimittelforschung* 1979;29:979-981.
176. Strum WB. Characteristics of the transport of pteroylglutamate and amethopterin in rat jejunum. *J Pharmacol Exp Ther* 1981;216:329-333.
177. Hoppner K, Lampi B. Bioavailability of folate following ingestion of cholestyramine in the rat. *Int J Vitam Nutr Res* 1991;61:130-134.
178. Farah JR, Kwiterovich PO Jr, Neill CA. Dose-effect relation of cholestyramine in children and young adults with familial hypercholesterolaemia. *Lancet* 1977;1:59-63.
179. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. *Arch Dis Child* 1996;74:157-160.
180. Tonstad S, Refsum H, Ose L, Ueland PM. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. *J Pediatr* 1998;132:365-368.
181. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. *Br J Rheumatol* 1995;34 Suppl 2:20-25.
182. Merino-Sanjuan M, Carrera A, Monte E, Jimenez-Torres NV. Adsorption of methotrexate and calcium leucovorin onto cholestyramine in vitro. *Int J Pharm* 2004;278:283-291.
183. Fernandez Megia MJ, Alos Alminana M, Terol Castera MJ. [Managing methotrexate toxicity: a case report]. *Farm Hosp* 2004;28:371-374.
184. Luketic GC, Santini R Jr, Butterworth CE Jr. Depression of whole blood folate activity by colchicine. *Proc Soc Exp Biol Med* 1965;120:13-16.
185. Bissonnette R, Treacy E, Rozen R et al. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. *Atherosclerosis* 2001;155:455-462.
186. Dierkes J, Westphal S, Luley C. Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management. *Drug Saf* 2003;26:81-91.
187. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. *Expert Opin Drug Saf* 2004;3:101-111.
188. Legendre C, Causse E, Chaput E et al. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect. *Biochem Biophys Res Commun* 2002;295:1052-1056.
189. Luc G, Jacob N, Bouly M et al. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. *J Cardiovasc Pharmacol* 2004;43:452-453.
190. Melenovsky V, Stulec T, Kozich V et al. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. *Am Heart J* 2003;146:110.
191. De Lorgeril M, Salen P, Paillard F et al. Lipid-lowering drugs and homocysteine. *Lancet* 1999;353:209-210.
192. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. *Lancet* 1999;354:219-220.
193. Dierkes J, Westphal S, Kunstmann S et al. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. *Atherosclerosis* 2001;158:161-164.
- 193a. Mayer O Jr, Simon J, Holubec L et al. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. *Eur J Clin Pharmacol* 2003;59(5-6):367-371.
194. Milionis HJ, Papakostas J, Kakafika A et al. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. *J Clin Pharmacol* 2003;43:825-830.
195. Papakostas GI, Petersen T, Mischoulon D et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder. Part 1. Predictors of clinical response in fluoxetine-resistant depression. *J Clin Psychiatry* 2004;65:1090-1095.
196. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. *J Psychopharmacol* 2004;18:251-256.
197. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. *J Psychopharmacol* 2005;19:59-65.
198. Bjelland I, Tell GS, Vollset SE et al. Folate, vitamin B12, homocysteine, and the MTHFR 677C→T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. *Arch Gen Psychiatry* 2003;60:618-626.

## Citations and Reference Literature: Folic Acid

199. Wilkinson AM, Anderson DN, Abou-Saleh MT et al. 5-Methyltetrahydrofolate level in the serum of depressed subjects and its relationship to the outcome of ECT. *J Affect Disord* 1994;32:163-168.
200. Mischoulon D. The role of folate in major depression: mechanisms and clinical implications. *Am Soc Clin Psychopharmacol Prog Notes* 1996;7:4-5.
201. Ramos MI, Allen LH, Haan MN et al. Plasma folate concentrations are associated with depressive symptoms in elderly Latina women despite folic acid fortification. *Am J Clin Nutr* 2004;80:1024-1028.
202. Mischoulon D, Burger JK, Spillmann MK et al. Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. *J Psychosom Res* 2000;49:183-187.
203. Fava M, Borus JS, Alpert JE et al. Folate, vitamin B12, and homocysteine in major depressive disorder. *Am J Psychiatry* 1997;154:426-428.
204. Papakostas GI, Petersen T, Mischoulon D et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder. Part 2. Predictors of relapse during the continuation phase of pharmacotherapy. *J Clin Psychiatry* 2004;65:1096-1098.
205. Papakostas GI, Petersen T, Lebowitz BD et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. *Int J Neuropsychopharmacol* 2005;1:1-6.
206. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo-controlled trial. *J Affect Disord* 2000;60:121-130.
207. Zanotelli F, Perusi O. [Possibilities and limitations of multiple chemoantibiotics in treatment of chronic pulmonary tuberculosis]. *G Ital Mal Torace* 1966;20:365-378.
208. Zajaczkowska J, Krychniak W, Krakowka P, Buraczewska M. Results of one-year chemotherapy with isoniazid (INH), streptomycin (SM) and ethionamide (ETA) in previously untreated patients with cavernous pulmonary tuberculosis. *Pol Med J* 1966;5:339-344.
209. Roberts PD, Hoffbrand AV, Mollin DL. Iron and folate metabolism in tuberculosis. *BMJ* 1966;5507:198-202.
210. Markkanen T, Levanto A, Sallinen V, Virtanen S. Folic acid and vitamin B12 in tuberculosis. *Scand J Haematol* 1967;4:283-291.
211. Klipstein FA, Berlinger FC, Reed LJ. Folate deficiency associated with drug therapy for tuberculosis. *Blood* 1967;29:697-712.
212. Evans DI, Attock B. Folate deficiency in pulmonary tuberculosis: relationship to treatment and to serum vitamin A and beta-carotene. *Tubercle* 1971;52:288-294.
213. Cameron SJ, Horne NW. The effect of tuberculosis and its treatment on erythropoiesis and folate activity. *Tubercle* 1971;52:37-48.
214. Line DH, Seitanidis B, Morgan JO, Hoffbrand AV. The effects of chemotherapy on iron, folate, and vitamin B12 metabolism in tuberculosis. *Q J Med* 1971;40:331-340.
215. Chabbou A, Maalej M, Zbiba M et al. [Analytic study of 80 cases of pulmonary tuberculosis treated with the INH-STRE-PAS regimen during 1971-2]. *Tunis Med* 1974;52:305-311.
216. Wada M. [The adverse reactions of anti-tuberculosis drugs and its management]. *Nippon Rinsho* 1998;56:3091-3095.
217. Bate J, Cole AJ. Rifampicin and the assay of folate and vitamin B12. *Med Lab Technol* 1974;31:199-203.
218. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease. *J Neural Transm Suppl* 2004;15-20.
219. Kuhn W, Roebroek R, Blom H et al. Elevated plasma levels of homocysteine in Parkinson's disease. *Eur Neurol* 1998;40:225-227.
220. Zoccolella S, Lamberti P, Armenise E et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. *Parkinsonism Relat Disord* 2005;11:131-133.
221. Miller JW, Shukitt-Hale B, Villalobos-Molina R et al. Effect of l-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. *Clin Neuropharmacol* 1997;20:55-66.
222. Yassin MS, Cheng H, Ekblom J, Orelund L. Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain. *Neurochem Int* 1998;32:53-59.
223. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of l-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. *J Nutr Biochem* 1997;8:634-640.
224. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. *Lancet* 1999;354:126-127.
225. Yasui K, Nakaso K, Kowa H et al. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. *Acta Neurol Scand* 2003;108:66-67.
226. Muller T, Woitalla D, Hauptmann B et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. *Neurosci Lett* 2001;308:54-56.
227. Muller T, Woitalla D, Fowler B, Kuhn W. 3-OMD and homocysteine plasma levels in parkinsonian patients. *J Neural Transm* 2002;109:175-179.

## Citations and Reference Literature: Folic Acid

228. Rogers JD, Sanchez-Saffon A, Frol AB, Díaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. *Arch Neurol* 2003;60:59-64.
229. Miller JW, Selhub J, Nadeau MR et al. Effect of l-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. *Neurology* 2003;60:1125-1129.
- 229a. Lokk J. [Treatment with levodopa can affect latent vitamin B12 and folic acid deficiency. Patients with Parkinson disease run the risk of elevated homocysteine levels]. *Lakartidningen* 2003;100(35):2674-2677. (Review)
230. Yasui K, Kowa H, Nakaso K et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. *Neurology* 2000;55:437-440.
231. O'Suilleabhain PE, Sung V, Hernández C et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. *Arch Neurol* 2004;61:865-868.
232. Muller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. *Arch Neurol* 2004;61:657-660.
233. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Jr. et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. *Mov Disord* 2004;19:1403-1408.
234. Lamberti P, Zoccolella S, Iliceto G et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. *Mov Disord* 2005;20:69-72.
235. Valkovic P, Benetin J, Blazicek P et al. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. *Parkinsonism Relat Disord* 2005;11:253-256.
236. Chen H, Zhang SM, Schwarzschild MA et al. Folate intake and risk of Parkinson's disease. *Am J Epidemiol* 2004;160:368-375.
237. Lamberti P, Zoccolella S, Armenise E et al. Hyperhomocysteinemia in l-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. *Eur J Neurol* 2005;12:365-368.
238. Stern SL, Brandt JT, Hurley RS et al. Serum and red cell folate concentrations in outpatients receiving lithium carbonate. *Int Clin Psychopharmacol* 1988;3:49-52.
239. Lee S, Chow CC, Shek CC et al. Folate concentration in Chinese psychiatric outpatients on long-term lithium treatment. *J Affect Disord* 1992;24:265-270.
240. Coppen A, Abou-Saleh MT. Plasma folate and affective morbidity during long-term lithium therapy. *Br J Psychiatry* 1982;141:87-89.
241. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. *J Affect Disord* 1986;10:9-13.
242. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. *Ann Intern Med* 1997;126:608-614.
243. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. *Ann Intern Med* 1998;129:716-718.
244. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. *J Natl Cancer Inst* 1999;91:2001-2008.
245. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. *Drug Metab Dispos* 2001;29:601-605.
246. Evans WE, Hon YY, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. *J Clin Oncol* 2001;19:2293-2301.
247. Ma XL, Zhu P, Wu MY et al. [Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia]. *Zhonghua Er Ke Za Zhi* 2003;41:929-933.
248. Formea CM, Myers-Huentelman H, Wu R et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. *Am J Transplant* 2004;4:1810-1817.
249. Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. *JAMA* 2005;293:1485-1489.
250. Achkar JP, Stevens T, Easley K et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2004;10:339-345.
251. Marinaki AM, Ansari A, Duley JA et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). *Pharmacogenetics* 2004;14:181-187.
252. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. *Pharmacogenetics* 2004;14:779-781.
253. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. *Liver Transpl* 2005;11:826-833.

## Citations and Reference Literature: Folic Acid

254. Zazgornik J, Druml W, Balcke P et al. Diminished serum folic acid levels in renal transplant recipients. *Clin Nephrol* 1982;18:306-310.
255. Lennard L, Lilleyman JS, Maddocks JL. The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia. *Br J Cancer* 1986;53:115-119.
- 255a. Schroder H, Clausen N, Ostergaard E, Pressler T. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. *Pediatr Hematol Oncol* 1986;3(3):241-247.
256. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. *Dig Dis Sci* 1994;39:1638-1641.
257. Caspary WF. Biguanides and intestinal absorptive function. *Acta Hepatogastroenterol (Stuttg)* 1977;24:473-480.
258. Bauman WA, Shaw S, Jayatilleke E et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. *Diabetes Care* 2000;23:1227-1231.
259. Wolever TMS, Assif L, Basu T et al. Miglitol, an alpha-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. *Nutr Res* 2000;20:1447-1456.
260. Andres E, Perrin AE, Demangeat C et al. The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine: a monocentric cohort study of 80 patients. *Eur J Intern Med* 2003;14:221-226.
261. Sorensen TK, Malinow MR, Williams MA et al. Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia. *Gynecol Obstet Invest* 1999;48:98-103.
262. Vrbikova J, Bicikova M, Tallowa J et al. Homocysteine and steroid levels in metformin-treated women with polycystic ovary syndrome. *Exp Clin Endocrinol Diabetes* 2002;110:74-76.
263. Fiorina P, Lanfredini M, Montanari A et al. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. *Am J Hypertens* 1998;11:1100-1107.
264. Smulders YM, Rakic M, Slaats EH et al. Fasting and post-methionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. *Diabetes Care* 1999;22:125-132.
265. Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease: a cardiologic standpoint. *Herz* 2004;29:290-298.
266. Forman JP, Rimm EB, Stampfer MJ, Curhan GC. Folate intake and the risk of incident hypertension among US women. *JAMA* 2005;293:320-329.
267. Carpentier JL, Bury J, Luyckx A, Lefebvre P. Vitamin B12 and folic acid serum levels in diabetics under various therapeutic regimens. *Diabete Metab* 1976;2:187-190.
268. Callaghan TS, Hadden DR, Tomkin GH. Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment. *Br Med J* 1980;280:1214-1215.
- 268a. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. *N Engl J Med* 1995;333(9):541-549.
269. Hoogeveen EK, Kostense PJ, Jakobs C et al. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? *J Intern Med* 1997;242:389-394.
270. Carlsen SM, Folling I, Grill V et al. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. *Scand J Clin Lab Invest* 1997;57:521-527.
271. Hermann LS, Kalen J, Katzman P et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. *Diabetes Obes Metab* 2001;3:428-434.
272. Hermann LS, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. *Br J Diabetes Vasc Dis* 2004;4:401-406.
273. Wulffele MG, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J Intern Med* 2003;254:455-463.
274. Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. *J Intern Med* 1998;244:169-174.
275. Child DF, Hudson PR, Jones H et al. The effect of oral folic acid on glutathione, glycaemia and lipids in type 2 diabetes. *Diabetes Nutr Metab* 2004;17:95-102.
276. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393-403.
277. Molitch ME, Fujimoto W, Hamman RF, Knowler WC. The Diabetes Prevention Program and its global implications. *J Am Soc Nephrol* 2003;14:S103-S107.
278. Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. *Ann Intern Med* 2005;142:611-619.

## Citations and Reference Literature: Folic Acid

279. Robinson C, Weigly E. Basic Nutrition and Diet Therapy. New York: Macmillan; 1984.
280. Roe DA. Drug-Induced Nutritional Deficiencies. 2nd ed. Westport, Conn: Avi Publishing; 1985.
281. Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. Drugs and Nutrients: the Interactive Effects. New York: Marcel Dekker; 1984:505-523.
282. Faloon WW, Paes IC, Woolfolk D et al. Effect of neomycin and kanamycin upon intestinal absorption. Ann NY Acad Sci 1966;132:879-887.
283. Hardison WG, Rosenberg IH. The effect of neomycin on bile salt metabolism and fat digestion in man. J Lab Clin Med 1969;74:564-573.
284. Sydow K, Daiber A, Oelze M et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004;113:482-489.
285. Loscalzo J. Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. Circulation 2001;104:1086-1088.
286. Pritchard KA Jr, Groszek L, Smalley DM et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-518.
287. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-C1437.
288. Verhaar MC, Wever RM, Kastelein JJ et al. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-241.
289. Stroes ES, van Faassen EE, Yo M et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-1134.
290. Kaesemeyer WH, Ogonowski AA, Jin L et al. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate. Br J Pharmacol 2000;131:1019-1023.
291. Wilmink HW, Stroes ES, Erkelens WD et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000;20:185-188.
292. Leopold JA, Loscalzo J. Organic nitrate tolerance and endothelial dysfunction: role of folate therapy. Minerva Cardioangiologica 2003;51:349-359.
293. Bec N, Gorren AC, Voelker C et al. Reaction of neuronal nitric-oxide synthase with oxygen at low temperature: evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem 1998;273:13502-13508.
294. Huang A, Vita JA, Venema RC, Keaney JF Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000;275:17399-17406.
295. Mayer B, Pitters E, Pfeiffer S et al. A synthetic peptide corresponding to the putative dihydrofolate reductase domain of nitric oxide synthase inhibits uncoupled NADPH oxidation. Nitric Oxide 1997;1:50-55.
296. Gruhn N, Aldershvile J, Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol 2001;416:245-249.
297. Gori T, Burstein JM, Ahmed S et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001;104:1119-1123.
298. Chanarin I. Cobalamins and nitrous oxide: a review. J Clin Pathol 1980;33:909-916.
299. Flippo TS, Holder WD Jr. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg 1993;128:1391-1395.
300. Drummond JT, Matthews RG. Nitrous oxide inactivation of cobalamin-dependent methionine synthase from *Escherichia coli*: characterization of the damage to the enzyme and prosthetic group. Biochemistry 1994;33:3742-3750.
301. Amos RJ, Amess JA, Hinds CJ, Mollin DL. Investigations into the effect of nitrous oxide anaesthesia on folate metabolism in patients receiving intensive care. Chemioterapia 1985;4:393-399.
302. Shane B, Stokstad EL. The interrelationships among folate, vitamin B12, and methionine metabolism. Adv Nutr Res 1983;5:133-170.
303. Ermens AA, Schoester M, Lindemans J, Abels J. Effect of nitrous oxide and methotrexate on folate coenzyme pools of blast cells from leukemia patients. Leuk Res 1991;15:165-171.
304. Horne DW, Holloway RS. Compartmentation of folate metabolism in rat pancreas: nitrous oxide inactivation of methionine synthase leads to accumulation of 5-methyltetrahydrofolate in cytosol. J Nutr 1997;127:1772-1775.
305. Herbert V, Zalusky R. Interrelations of vitamin B12 and folic acid metabolism: folic acid clearance studies. J Clin Invest 1962;41:1263-1276.
306. Green JM, Ballou DP, Matthews RG. Examination of the role of methylenetetrahydrofolate reductase in incorporation of methyltetrahydrofolate into cellular metabolism. FASEB J 1988;2:42-47.

## Citations and Reference Literature: Folic Acid

307. Keeling PA, Rocke DA, Nunn JF et al. Folinic acid protection against nitrous oxide teratogenicity in the rat. *Br J Anaesth* 1986;58:528-534.
308. Koblin DD, Tomerson BW, Waldman FM. Disruption of folate and vitamin B12 metabolism in aged rats following exposure to nitrous oxide. *Anesthesiology* 1990;73:506-512.
309. Koblin DD, Tomerson BW, Waldman FM et al. Effect of nitrous oxide on folate and vitamin B12 metabolism in patients. *Anesth Analg* 1990;71:610-617.
310. Ermens AA, Refsum H, Rupreht J et al. Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocysteine and folate in plasma and urine. *Clin Pharmacol Ther* 1991;49:385-393.
311. Salo M, Rajamaki A, Nikoskelainen J. Absence of signs of vitamin B12-nitrous oxide interaction in operating theatre personnel. *Acta Anaesthesiol Scand* 1984;28:106-108.
312. Nunn JF, Chanarin I, Tanner AG, Owen ER. Megaloblastic bone marrow changes after repeated nitrous oxide anaesthesia: reversal with folinic acid. *Br J Anaesth* 1986;58:1469-1470.
313. Selhub J, Dhar GJ, Rosenberg IH. Inhibition of folate enzymes by sulfasalazine. *J Clin Invest* 1978;61:221-224.
314. Baum CL, Selhub J, Rosenberg IH. Antifolate actions of sulfasalazine on intact lymphocytes. *J Lab Clin Med* 1981;97:779-784.
315. Krogh Jensen M, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. *Scand J Clin Lab Invest* 1996;56:421-429.
316. Oakley GP Jr, Adams MJ, Dickinson CM. More folic acid for everyone, now. *J Nutr* 1996;126:751S-755S.
317. Wertalik LF, Metz EN, LoBuglio AF, Balcerzak SP. Decreased serum B12 levels with oral contraceptive use. *JAMA* 1972;221:1371-1374.
318. Bielenberg J. [Folic acid and vitamin deficiency caused by oral contraceptives]. *Med Monatsschr Pharm* 1991;14:244-247.
319. Shojania AM, Hornady G, Barnes PH. Oral contraceptives and serum-folate level. *Lancet* 1968;291:1376-1377.
320. Food and Nutrition Board IoM. Folic acid. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B-6, Vitamin B-12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998:193-305.
321. Durand P, Prost M, Blache D. Folic acid deficiency enhances oral contraceptive-induced platelet hyperactivity. *Arterioscler Thromb Vasc Biol* 1997;17:1939-1946.
322. Lindenbaum J, Whitehead N, Reyner F. Oral contraceptive hormones, folate metabolism, and the cervical epithelium. *Am J Clin Nutr* 1975;28:346-353.
323. Mooij PN, Thomas CM, Doesburg WH, Eskes TK. Multivitamin supplementation in oral contraceptive users. *Contraception* 1991;44:277-288.
324. Steegers-Theunissen RP, Van Rossum JM, Steegers EA et al. Sub-50 oral contraceptives affect folate kinetics. *Gynecol Obstet Invest* 1993;36:230-233.
325. Green TJ, Houghton LA, Donovan U et al. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. *J Am Diet Assoc* 1998;98:49-55.
326. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. *J Clin Endocrinol Metab* 2005;90:3863-3870.
327. Martinez O, Roe DA. Effect of oral contraceptives on blood folate levels in pregnancy. *Am J Obstet Gynecol* 1977;128:255-261.
328. Whitehead N, Reyner F, Lindenbaum J. Megaloblastic changes in the cervical epithelium: association with oral contraceptive therapy and reversal with folic acid. *JAMA* 1973;226:1421-1424.
329. Butterworth CE Jr, Hatch KD, Gore H et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. *Am J Clin Nutr* 1982;35:73-82.
330. Zarcone R, Bellini P, Carfora E et al. [Folic acid and cervix dysplasia]. *Minerva Ginecol* 1996;48:397-400.
331. Kwasniewska A, Tukendorf A, Semczuk M. Folate deficiency and cervical intraepithelial neoplasia. *Eur J Gynaecol Oncol* 1997;18:526-530.
332. Sedjo RL, Inserra P, Abrahamsen M et al. Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. *Cancer Epidemiol Biomarkers Prev* 2002;11:353-359.
333. Roe DA. Diet and Drug Interactions. New York: Van Nostrand Reinhold; 1989.
334. Russell RM, Dutta SK, Oaks EV et al. Impairment of folic acid absorption by oral pancreatic extracts. *Dig Dis Sci* 1980;25:369-373.
335. Walzer PD, Kim CK, Foy JM et al. Inhibitors of folic acid synthesis in the treatment of experimental *Pneumocystis carinii* pneumonia. *Antimicrob Agents Chemother* 1988;32:96-103.
336. Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. *N Engl J Med* 1981;305:1513-1517.

## Citations and Reference Literature: Folic Acid

337. Longstreth GF, Green R. Folate status in patients receiving maintenance doses of sulfasalazine. *Arch Intern Med* 1983;143:902-904.
338. Gregory JF 3rd. Case study: folate bioavailability. *J Nutr* 2001;131:1376S-1382S.
339. Skold O. Sulfonamide resistance: mechanisms and trends. *Drug Resist Update* 2000;3:155-160.
340. Grindulis KA, McConkey B. Does sulphasalazine cause folate deficiency in rheumatoid arthritis? *Scand J Rheumatol* 1985;14:265-270.
341. Grieco A, Caputo S, Bertoli A et al. Megaloblastic anaemia due to sulphasalazine responding to drug withdrawal alone. *Postgrad Med J* 1986;62:307-308.
342. Longstreth GF, Green R. Folate levels in inflammatory bowel disease. *N Engl J Med* 1982;306:1488.
343. Ma J, Stampfer MJ, Giovannucci E et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res* 1997;57:1098-1102.
344. Ma J, Stampfer MJ, Christensen B et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 1999;8:825-829.
345. Eichholzer M, Luthy J, Moser U, Fowler B. Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. *Swiss Med Wkly* 2001;131:539-549.
346. Shannon B, Gnanasamanthan S, Beilby J, Iacopetta B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. *Gut* 2002;50:520-524.
347. Terry P, Jain M, Miller AB et al. Dietary intake of folic acid and colorectal cancer risk in a cohort of women. *Int J Cancer* 2002;97:864-867.
348. Pufulete M, Al-Ghnaniem R, Rennie JA et al. Influence of folate status on genomic DNA methylation in colonic mucosa of subjects without colorectal adenoma or cancer. *Br J Cancer* 2005;92:838-842.
349. Mason JB, Choi SW. The mechanisms by which folate depletion enhances colorectal carcinogenesis: a unified scheme. *Nestle Nutr Workshop Ser Clin Perform Programme* 2000;4:87-99; discussion 99-101.
350. Mason JB, Choi SW. Folate and carcinogenesis: developing a unifying hypothesis. *Adv Enzyme Regul* 2000;40:127-141.
351. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. *J Nutr* 2000;130:129-132.
352. Song J, Medline A, Mason JB et al. Effects of dietary folate on intestinal tumorigenesis in the *apcMin* mouse. *Cancer Res* 2000;60:5434-5440.
353. Kim YI, Baik HW, Fawaz K et al. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. *Am J Gastroenterol* 2001;96:184-195.
354. Khosraviani K, Weir HP, Hamilton P et al. Effect of folate supplementation on mucosal cell proliferation in high risk patients for colon cancer. *Gut* 2002;51:195-199.
355. Swinson CM, Perry J, Lumb M, Levi AJ. Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis. *Gut* 1981;22:456-461.
356. Lashner BA, Heidenreich PA, Su GL et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis: a case-control study. *Gastroenterology* 1989;97:255-259.
357. Lashner BA, Provencher KS, Seidner DL et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. *Gastroenterology* 1997;112:29-32.
- 357a. Norgard B, Czeizel AE, Rockenbauer M, et al. Population-based case control study of the safety of sulfasalazine use during pregnancy. *Aliment Pharmacol Ther* 2001;15(4):483-486.
358. Logan EC, Williamson LM, Ryrie DR. Sulphasalazine-associated pancytopenia may be caused by acute folate deficiency. *Gut* 1986;27:868-872.
359. Hoshino J, Sugawara K, Ishikawa S et al. [A case of ulcerative colitis with folate-deficient megaloblastic anemia induced by sulfasalazine]. *Nippon Shokakibyo Gakkai Zasshi* 1999;96:840-845.
360. Omray A, Varma KC. Evaluation of pharmacokinetic parameters of tetracycline hydrochloride upon oral administration with vitamin C and vitamin B complex. *Hindustan Antibiot Bull* 1981;23:33-37.
361. Shojania AM, Hornady G. Effect of antimicrobial agents on serum folate assay. *Am J Clin Pathol* 1969;52:454-456.
362. Banwell JG, Gorbach SL, Chatterjee B, Mitra R. Tropical sprue: a study of small intestinal function and the changes resulting from vitamin B12, folate, and tetracycline therapy. *Gut* 1968;9:725.
363. Klipstein FA, Samloff IM. Folate synthesis by intestinal bacteria. *Am J Clin Nutr* 1966;19:237-246.
364. Klipstein FA, Falaiye JM. Tropical sprue in expatriates from the tropics living in the continental United States. *Medicine (Baltimore)* 1969;48:475-491.
365. Westergaard H. Tropical sprue. *Curr Treat Options Gastroenterol* 2004;7:7-11.
366. Hanson JP. Tropical sprue in Far North Queensland. *Med J Aust* 2005;182:536-537.

## Citations and Reference Literature: Folic Acid

367. Zimmerman J, Selhub J, Rosenberg IH. Competitive inhibition of folic acid absorption in rat jejunum by triamterene. *J Lab Clin Med* 1986;108:272-276.
368. Schalhorn A, Siegert W, Sauer HJ. Antifolate effect of triamterene on human leucocytes and on a human lymphoma cell line. *Eur J Clin Pharmacol* 1981;20:219-224.
369. Tuckerman M, Turco S. Human Nutrition. Philadelphia: Lea & Febiger; 1983.
370. Jackson EK. Diuretics. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:706.
371. Maass AR, Wiebelhaus VD, Sosnowski G et al. Effect of triamterene on folic reductase activity and reproduction in the rat. *Toxicol Appl Pharmacol* 1967;10:413-423.
372. Mason JB, Zimmerman J, Otradovec CL et al. Chronic diuretic therapy with moderate doses of triamterene is not associated with folate deficiency. *J Lab Clin Med* 1991;117:365-369.
373. Amitai Y, Leventhal A. Folic acid antagonists during pregnancy and risk of birth defects. *N Engl J Med* 2001;344:933; author reply 934-935.
374. Morrow LE, Grimsley EW. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. *South Med J* 1999;92:866-870.
375. Lieberman FL, Bateman JR. Megaloblastic anemia possibly induced by triamterene in patients with alcoholic cirrhosis: two case reports. *Ann Intern Med* 1968;68:168-173.
376. Evers S, Di Padova K, Meyer M et al. Strategies towards a better understanding of antibiotic action: folate pathway inhibition in *Haemophilus influenzae* as an example. *Electrophoresis* 1998;19:1980-1988.
377. Kahn SB, Fein SA, Brodsky I. Effects of trimethoprim on folate metabolism in man. *Clin Pharmacol Ther* 1968;9:550-560.
378. Fleischman SH, Brooks CL 3rd. Protein-drug interactions: characterization of inhibitor binding in complexes of DHFR with trimethoprim and related derivatives. *Proteins* 1990;7:52-61.
379. Vinnicombe HG, Derrick JP. Dihydropteroate synthase from *Streptococcus pneumoniae*: characterization of substrate binding order and sulfonamide inhibition. *Biochem Biophys Res Commun* 1999;258:752-757.
380. Bjornson BH, McIntyre AP, Harvey JM, Tauber AI. Studies of the effects of trimethoprim and sulfamethoxazole on human granulopoiesis. *Am J Hematol* 1986;23:1-7.
381. Bygbjerg IC, Lund JT, Hording M. Effect of folic and folinic acid on cytopenia occurring during co-trimoxazole treatment of *Pneumocystis carinii* pneumonia. *Scand J Infect Dis* 1988;20:685-686.
382. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for *Pneumocystis carinii* pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. *J Infect Dis* 1994;170:912-917.
383. Systemic anti-infectives, miscellaneous anti-infectives, trimethoprim. In: Threlkeld DS, ed. Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons; August 1992:408-408a.
384. Sahai J. Urinary tract infections. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: the Clinical Use of Drugs. 6th ed. Vancouver, Wash: Applied Therapeutics; 1995:63-66.
385. Cronkite E, Bullis J, Honikel L. Partial amelioration of AZT-induced macrocytic anemia in the mouse by folic acid. *Stem Cells* 1993;11:393-397.
386. Tefferi A. Anemia in adults: a contemporary approach to diagnosis. *Mayo Clin Proc* 2003;78:1274-1280.
387. Romanelli F, Empey K, Pomeroy C. Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. *AIDS Patient Care STDS* 2002;16:405-411.
388. Manfredi R, Ricchi E, Costigliola P et al. [Monitoring of several hematological parameters of the erythroid series in patients with HIV infection treated with zidovudine]. *Recenti Prog Med* 1992;83:361-366.
389. Snower DP, Weil SC. Changing etiology of macrocytosis. Zidovudine as a frequent causative factor. *Am J Clin Pathol* 1993;99:57-60.
390. Falguera M, Perez-Mur J, Puig T, Cao G. Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine. *Eur J Haematol* 1995;55:97-102.
391. Gorbach SL, Bengt E. Gustafsson Memorial Lecture. Function of the normal human microflora. *Scand J Infect Dis Suppl* 1986;49:17-30.
392. Simon GL, Gorbach SL. The human intestinal microflora. *Dig Dis Sci* 1986;31:147S-162S.
393. De Simone C, Vesely R, Bianchi SB et al. The role of probiotics in modulation of the immune system in man and in animals. *Int J Immunother* 1993;9:23-28.
394. Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997;6 Suppl 1:S43-S45.
395. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. *JPEN J Parenter Enteral Nutr* 1997;21:357-365.

## Citations and Reference Literature: Folic Acid

396. Macfarlane GT, Macfarlane S. Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. *Scand J Gastroenterol Suppl* 1997;222:3-9.
397. Mombelli B, Gismondo MR. The use of probiotics in medical practice. *Int J Antimicrob Agents* 2000;16:531-536.
398. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. *J Am Diet Assoc* 2001;101:229-238; quiz 239-241.
399. Montalto M, Arancio F, Izzi D et al. [Probiotics: history, definition, requirements and possible therapeutic applications]. *Ann Ital Med Int* 2002;17:157-165.
400. Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. *Altern Med Rev* 2003;8:143-155.
401. Reid G, Sanders ME, Gaskins HR et al. New scientific paradigms for probiotics and prebiotics. *J Clin Gastroenterol* 2003;37:105-118.
402. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. *JAMA* 1995;274:1049-1057.
403. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. *J Am Coll Cardiol* 1996;27:517-527.
404. Ballal RS, Jacobsen DW, Robinson K. Homocysteine: update on a new risk factor. *Cleve Clin J Med* 1997;64:543-549.
405. Bronstrup A, Hages M, Prinz-Langenohl R, Pietrzik K. Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women. *Am J Clin Nutr* 1998;68:1104-1110.
406. Malinow MR, Duell PB, Hess DL et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N Engl J Med* 1998;338:1009-1015.
407. Giles WH, Kittner SJ, Croft JB et al. Serum folate and risk for coronary heart disease: results from a cohort of US adults. *Ann Epidemiol* 1998;8:490-496.
408. Rimm EB, Willett WC, Hu FB et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. *JAMA* 1998;279:359-364.
409. Prasad K. Homocysteine, a risk factor for cardiovascular disease. *Int J Angiol* 1999;8:76-86.
410. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. *Lancet* 1999;354:407-413.
411. Eikelboom JW, Lonn E, Genest J Jr et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. *Ann Intern Med* 1999;131:363-375.
412. Booth GL, Wang EE. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. *CMAJ* 2000;163:21-29.
413. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. *Ann Pharmacother* 2000;34:57-65.
414. Title LM, Cummings PM, Giddens K et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. *J Am Coll Cardiol* 2000;36:758-765.
415. Wald DS, Bishop L, Wald NJ et al. Randomized trial of folic acid supplementation and serum homocysteine levels. *Arch Intern Med* 2001;161:695-700.
416. Aguilar B, Rojas JC, Collados MT. Metabolism of homocysteine and its relationship with cardiovascular disease. *J Thromb Thrombolysis* 2004;18:75-87.
417. Strain JJ, Dowey L, Ward M et al. B-vitamins, homocysteine metabolism and CVD. *Proc Nutr Soc* 2004;63:597-603.
418. Landgren F, Israelsson B, Lindgren A et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. *J Intern Med* 1995;237:381-388.
419. Dongari A, McDonnell HT, Langlais RP. Drug-induced gingival overgrowth. *Oral Surg Oral Med Oral Pathol* 1993;76:543-548.
420. Chowers Y, Sela BA, Holland R et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. *Am J Gastroenterol* 2000;95:3498-3502.
421. Refai TM, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. *Clin Rheumatol* 2002;21:457-461.
422. Roe D, Campbell T. Drugs and Nutrients: the Interactive Effects. New York: Marcel Dekker; 1984:288-289, 505-523.
423. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. *Pharmacogenom J* 2001;1:65-70.
424. Zhu AX, Puchalski TA, Stanton VP Jr et al. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. *Clin Colorectal Cancer* 2004;3:225-234.
425. Mainwaring P, Grygiel JJ. Interaction of 5-fluorouracil with folates. *Aust NZ J Med* 1995;25:60.
426. Den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. *N Engl J Med* 1996;334:759-762.
427. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. *Annu Rev Med* 1998;49:31-62.

## Citations and Reference Literature: Folic Acid

428. Robinson K, Arheart K, Refsum H et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. *Circulation* 1998;97:437-443.
429. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* 1999;99:178-182.
430. Christensen B, Landaas S, Stensvold I et al. Whole blood folate, homocysteine in serum, and risk of first acute myocardial infarction. *Atherosclerosis* 1999;147:317-326.
431. Joshi UM, Virkar KD, Amatayakul K et al. Impact of hormonal contraceptives vis-a-vis non-hormonal factors on the vitamin status of malnourished women in India and Thailand. World Health Organization: Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Oral Contraceptives. *Hum Nutr Clin Nutr* 1986;40:205-220.
432. Clarke SJ, Hanwell J, de Boer M et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. *J Clin Oncol* 1996;14:1495-1503.
433. Kohne CH, Thuss-Patience P, Friedrich M et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. *Br J Cancer* 1998;77:973-977.
434. AstraZeneca. Product Information: Tomudex®, raltitrexed disodium. Mississauga, Ontario; 2000.
435. McKinley MC, McNulty H, McPartlin J et al. Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. *Am J Clin Nutr* 2001;73:759-764.
436. Tucker KL, Olson B, Bakun P et al. Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial. *Am J Clin Nutr* 2004;79:805-811.
437. Moat SJ, Ashfield-Watt PA, Powers HJ et al. Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype. *Clin Chem* 2003;49:295-302.
438. McNulty H, Dowey LC, Scott JM. Riboflavin supplementation lowers plasma homocysteine in individuals homozygous for the MTHFR C677T polymorphism. *J Inherit Metab Dis* 2003;26 Suppl 1:12.
439. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001;345:1593-1600.
440. Sato Y, Honda Y, Iwamoto J et al. Effect of folate and mecabalamin on hip fractures in patients with stroke: a randomized controlled trial. *JAMA* 2005;293:1082-1088.
441. Sato Y, Honda Y, Iwamoto J et al. Homocysteine as a predictive factor for hip fracture in stroke patients. *Bone* 2005;36:721-726.
442. Mukherjee MD, Sandstead HH, Ratnaparkhi MV et al. Maternal zinc, iron, folic acid, and protein nutriture and outcome of human pregnancy. *Am J Clin Nutr* 1984;40:496-507.
443. Milne DB, Canfield WK, Mahalko JR, Sandstead HH. Effect of oral folic acid supplements on zinc, copper, and iron absorption and excretion. *Am J Clin Nutr* 1984;39:535-539.
444. Simmer K, Pearson TC, Wheeler MJ, Thompson RP. Zinc status in polycythaemia. *Eur J Haematol* 1987;38:433-436.
445. Butterworth CE Jr, Tamura T. Folic acid safety and toxicity: a brief review. *Am J Clin Nutr* 1989;50:353-358.
446. Kauwell GP, Bailey LB, Gregory JF 3rd et al. Zinc status is not adversely affected by folic acid supplementation and zinc intake does not impair folate utilization in human subjects. *J Nutr* 1995;125:66-72.
447. Strandhagen E, Landaas S, Thelle DS. Folic acid supplement decreases the homocysteine increasing effect of filtered coffee: a randomised placebo-controlled study. *Eur J Clin Nutr* 2003;57:1411-1417.

## Reference Literature

- [No author given.] Folate-responsive homocystinuria and "schizophrenia." *Nutr Rev* 1982;40:242-245.
- [No authors listed.] Guidelines for monitoring drug therapy in rheumatoid arthritis: American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. *Arthritis Rheum* 1996;39(5):723-731.
- [No author given.] How folate fights disease. *Nature Struct Biol* 1999;6:293-294.
- [No author given.] Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR Morb Mortal Wkly Rep* 1992;42(RR-14):1-7.
- [No author given.] Sulfasalazine inhibits folate absorption. *Nutr Rev* 1988;46(9):320-323.
- Adams JF, Clark JS, Ireland JT, et al. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. *Diabetologia* 1983;24:16-18.
- Adank C, Green TJ, Skeaff CM, et al. Weekly high-dose folic Acid supplementation is effective in lowering serum homocysteine concentrations in women. *Ann Nutr Metab* 2003;47(2):55-59.
- Adinolfi LE, Ingrosso D, Cesaro G, et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. *Hepatology* 2005;41(5):995-1003.

## Citations and Reference Literature: Folic Acid

- Aguilar B, Rojas JC, Collados MT. Metabolism of homocysteine and its relationship with cardiovascular disease. *J Thromb Thrombolysis* 2004;18(2):75-87.
- Ahn E, Kapur B, Koren G. Study on circadian variation in folate pharmacokinetics. *Can J Clin Pharmacol* 2005;12(1):e4-9.
- Alati T, Worzalla JF, Shih C, et al. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. *Cancer Res* 1996;56(10):2331-2335.
- Al-Delaimy WK, Rexrode KM, Hu FB, et al. Folate intake and risk of stroke among women. *Stroke* 2004;35(6):1259-1263.
- Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. *J Biol Chem* 1985;260(17):9720-9726.
- Alpert JE, Fava M. Nutrition and depression: the role of folate. *Nutr Rev* 1997;55(5):145-149.
- Alfthan G, Laurinen MS, Valsta LM, et al. Folate intake, plasma folate and homocysteine status in a random Finnish population. *Eur J Clin Nutr* 2003;57(1):81-88.
- Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. *Lancet* 1997;349:397.
- Almadori G, Bussu F, Galli J, et al. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. *Cancer* 2005;103(2):284-292.
- Almadori G, Bussu F, Navarra P, et al. Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. *Cancer* 2006;107(2):328-336.
- Also-Rallo E, Lopez-Quesada E, Urreizti R, et al. Polymorphisms of genes involved in homocysteine metabolism in preeclampsia and in uncomplicated pregnancies. *Eur J Obstet Gynecol Reprod Biol* 2005;120(1):45-52.
- Ames BN. A role for supplements in optimizing health: the metabolic tune-up. *Arch Biochem Biophys* 2004;423(1):227-234. (Review)
- Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. *Mutat Res* 2001;475(1-2):7-20. (Review)
- Ames BN. Increasing longevity by tuning up metabolism: to maximize human health and lifespan, scientists must abandon outdated models of micronutrients. *EMBO Rep* 2005;6(Suppl 1):S20-24. (Review)
- Ames BN. Micronutrient deficiencies: a major cause of DNA damage. *Ann N Y Acad Sci* 1999;889:87-106. (Review)
- Ames BN. The metabolic tune-up: metabolic harmony and disease prevention. *J Nutr* 2003;133(5):1544S-1548S.
- Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. *Mol Aspects Med* 2005;26(4-5):363-378. (Review)
- Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K<sub>m</sub>): relevance to genetic disease and polymorphisms. *Am J Clin Nutr* 2002;75(4):616-658. (Review)
- Amitai Y, Fisher N, Haringman M, et al. Increased awareness, knowledge and utilization of preconceptional folic acid in Israel following a national campaign. *Prev Med* 2004;39(4):731-737.
- Amos RJ, Amess JA, Hinds CJ, et al. Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care. *Lancet* 1982;2:835-838.
- Andrès E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. *Arch Intern Med* 2002;162:2251-2252.
- Andrès E, Perrin A-E, Demangeat C, et al. The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine: a monocentric cohort study of 80 patients. *Eur J Intern Med* 2003;14:221-226.
- Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. *Aliment Pharmacol Ther* 2002;16(10):1743-1750.
- Apeland T, Mansoor MA, Pentieva K, et al. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. *Clin Chem* 2003;49(6 Pt 1):1005-1008.
- Arakawa T, Narisawa K, Tanno K, et al. Megaloblastic anemia and mental retardation associated with hyperfolic-acidemia: probably due to N5 methyltetrahydrofolate transferase deficiency. *Tohoku J Exp Med* 1967;93:1-22.
- Arakawa T. Congenital defects in folate utilization. *Am J Med* 1970;48:594-598.
- Arinami T, Yamada N, Yamakawa-Kobayashi K, et al. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. *Am J Med Genet* 1997;74:526-528.
- Ashfield-Watt PA, Pullin CH, Whiting JM, et al. Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. *Am J Clin Nutr* 2002;76(1):180-186.
- Ashfield-Watt PA, Whiting JM, Clark ZE, et al. A comparison of the effect of advice to eat either '5-a-day' fruit and vegetables or folic acid-fortified foods on plasma folate and homocysteine. *Eur J Clin Nutr* 2003;57(2):316-323.
- Auer J, Berent R, Weber T, et al. [Homocysteine and cardiovascular risk] *Wien Med Wochenschr* 2001;151(1-2):25-28. (Review) [German]

## Citations and Reference Literature: Folic Acid

- Bach Kristensen M, Tetens I, Alstrup Jorgensen AB, et al. A decrease in iron status in young healthy women after long-term daily consumption of the recommended intake of fibre-rich wheat bread. *Eur J Nutr* 2005;44(6):334-340.
- Baggett JE, Morgan SL, Ha TS, et al. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. *Clin Exp Rheumatol* 1993;11(Suppl 8):S101-105. (Review)
- Bagree R, Gibby OM, Penney MD, et al. Prevalence of vitamin B12 deficiency with metformin treatment. *Diabetic Med* 1999;16(suppl 1):P61.
- Bailey LB. Dietary reference intakes for folate: the debut of dietary folate equivalents. *Nutr Rev* 1998;56(10):294-299.
- Bailey LB. Folate and vitamin B12 recommended intakes and status in the United States. *Nutr Rev* 2004;62(6 Pt 2):S14-21. (Review)
- Bailey LB. Folate, methyl-related nutrients, alcohol, and the MTHFR 677C→T polymorphism affect cancer risk: intake recommendations. *J Nutr* 2003;133(11 Suppl 1):3748S-3753S. (Review)
- Bailey LB. New standard for dietary folate intake in pregnant women. *Am J Clin Nutr* 2000;71(5 Suppl):1304S-1307S. (Review)
- Bailey LB, Duhaney RL, Maneval DR, et al. Vitamin B-12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms. *J Nutr* 2002;132(7):1872-1878.
- Bailey LB, Gregory JF III. Folate metabolism and requirements. *J Nutr* 1999;129(4):779-782.
- Bailey LB, Berry RJ. Folic acid supplementation and the occurrence of congenital heart defects, orofacial clefts, multiple births, and miscarriage. *Am J Clin Nutr* 2005;81:1213-1217.
- Bailey LB, Gregory JF III. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. *J Nutr* 1999;129(5):919-922.
- Bailey LB, Gregory JF, Caudill M, et al. The relationship between increased folate stetabolism and the increased requirement for folate in pregnancy. *Br J Obstet Gynaecol* 2001;108(7):772-773.
- Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. *J Clin Endocrinol Metab* 2005;90(7):3863-3870.
- Baron JA, Sandler RS, Haile RW, et al. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. *J Natl Cancer Inst* 1998;90:57-62.
- Bates CJ, Fuller NJ. The effect of riboflavin deficiency on methylene tetrahydrofolate reductase (NADPH) (EC 1.5.1.20) and folate metabolism in the rat. *Br J Nutr* 1985;55:455-464.
- Bayly AM, Berglez JM, Patel O, et al. Folic acid utilisation related to sulfa drug resistance in *Saccharomyces cerevisiae*. *FEMS Microbiol Lett* 2001;204(2):387-390.
- Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. *Drug Safety* 1998;19(5):355-371. (Review)
- Bazzano LA, He J, Ogden LG, et al. Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study: National Health and Nutrition Examination Survey. *Stroke* 2002;33:1183-1188.
- Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA* 2006;296:2720-2726. (Meta-analysis)
- Beaulieu AJ, Gohh RY, Han H, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. *Arterioscler Thromb Vasc Biol* 1999;19:2918-2921.
- Beck WS. Drugs and the intestinal absorption of folate. *J Lab Clin Med* 1986;108(4):263-264.
- Becker A, Henry RM, Kostense PJ, et al. Plasma homocysteine and S-adenosylmethionine in erythrocytes as determinants of carotid intima-media thickness: different effects in diabetic and non-diabetic individuals: the Hoorn Study. *Atherosclerosis* 2003;169(2):323-330. Erratum in *Atherosclerosis* 2004;173(1):153.
- Becker A, Smulders YM, Teerlink T, et al. S-adenosylhomocysteine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine are not related to folate, cobalamin and vitamin B6 concentrations. *Eur J Clin Invest* 2003;33(1):17-25.
- Bellamy MF, McDowell IF, Ramsey MW, et al. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. *Eur J Clin Invest* 1999;29(8):659-662.
- Benito E, Stigglebout A, Bosch FX, et al. Nutritional factors in colorectal cancer risk: a case-control study in Majorca. *Int J Cancer* 1991;49:161-167.
- Benn A, Swan CH, Cooke WT, et al. Effect of intraluminal pH on the absorption of pteroylmonoglutamic acid. *Br Med J* 1971;1(741):148-150.
- Bentley TG, Willett WC, Weinstein MC, et al. Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. *Am J Public Health* 2006;96(11):2040-2047.
- Benzinger P, Alscher DM. [Untreated homocystinuria in adulthood] *Dtsch Med Wochenschr* 2005;130(43):2439-2443. [German]
- Berg MJ, Fincham RW, Ebert BE, et al. Decrease of serum folates in healthy male volunteers taking phenytoin. *Epilepsia* 1988;29(1):67-73.

## Citations and Reference Literature: Folic Acid

- Berg MJ, Rivey MP, Vern BA, et al. Phenytoin and folic acid: individualized drug-drug interaction. *Ther Drug Monit* 1983;5:395-399.
- Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. *N Engl J Med* 1999;341:1485-1490.
- Bilsborough W, Green DJ, Mamotte CD, et al. Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function. *Atherosclerosis* 2003;169(1):131-138.
- Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 2005;42(2):481-489.
- Bleie O, Refsum H, Ueland PM, et al. Changes in basal and postmethionine load concentrations of total homocysteine and cystathione after B vitamin intervention. *Am J Clin Nutr* 2004;80(3):641-648.
- Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. *Proc Natl Acad Sci U S A* 1997;94(7):3290-3295.
- Blount BC, Ames BN. DNA damage in folate deficiency. *Baillieres Clin Haematol* 1995;8(3):461-78. (Review)
- Blouvier B, Duvulder B. Folic acid, xanthine oxidase, and uric acid. *Ann Intern Med* 1978;88(2):269. (Letter)
- Bocci G, Danesi R, Di Paolo AD, et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydroxuracil after conventional and reduced test dose in cancer patients. *Clin Cancer Res* 2000;6:3032-3728.
- Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. *Pediatrics* 2006;117:803-813.
- Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* 2006;354(15):1578-1588.
- Boss GR, Ragsdale RA, Zettner A, et al. Failure of folic acid (pteroylglutamic acid) to affect hyperuricemia. *J Lab Clin Med* 1980;96:783-789.
- Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients: a randomized, placebo-controlled trial. *Ann Intern Med* 1997;127:1089-1092.
- Bostom AG, Jacques PF, Liaugaudas G, et al. Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour. *Arterioscler Thromb Vasc Biol* 2002;22(3):488-491.
- Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. *Ann Intern Med* 1999;131(5):352-355.
- Bostom AG, Silbershatz H, Rosenberg IH, et al. Non-fasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med* 1999;159:1077-1080.
- Botez MI. Folate deficiency and neurological disorders in adults. *Med Hypothesis* 1976;2:135-140.
- Botez MI, Cadotte M, Beaulieu R, et al. Neurologic disorders responsive to folic acid therapy. *Can Med Assoc J* 1976;115(3):217-223.
- Botez MI, Botez T, Ross-Chouinard A, et al. Thiamine and folate treatment of chronic epileptic patients: a controlled study with the Wechsler IQ scale. *Epilepsy Res* 1993;16(2):157-163.
- Bottiglieri ET, Crellin RF, Reynolds EH. Folates and neuropsychiatry. In: Bailey LB, ed. *Folates in health and disease*. New York: Marcel Dekker; 1995:435-462.
- Bottiglieri T, Diaz-Arrastia R. Hyperhomocysteinemia and cognitive function: more than just a casual link? *Am J Clin Nutr* 2005;82(3):493-494.
- Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. *J Neurol Neurosurg Psychiatry* 2000;69(2):228-232.
- Bottiglieri T, Parnetti L, Arning E, et al. Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia. *Mech Ageing Dev* 2001;122(16):2013-2023.
- Botto LD, Lisi A, Robert-Gnansia E, et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? *BMJ* 2005;330(7491):571.
- Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. *JAMA* 1995;274:1049-1057.
- Branda RF, Moldow CF, MacArthur JR, et al. Folate-induced remission in aplastic anemia with familial defect of cellular folate uptake. *N Engl J Med* 1978;298:469-475.
- Branda RF, Nelson NL. Inhibition of 5-methyltetrahydrofolic acid transport by amphipathic drugs. *Drug Nutr Interact* 1981;1(1):45-53.
- Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. *Metabolism* 1985;34(11):1073-1077.
- Brattstrom L, Israelsson B, Olsson A. Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma. *Scand J Clin Lab Invest* 1992;52(4):283-287.
- Brent RL, Oakley GP Jr. The folate debate. *Pediatrics* 2006;117(4):1418-1419. (Editorial)
- Brent RL, Oakley GP Jr. The Food and Drug Administration must require the addition of more folic acid in "enriched" flour and other grains. *Pediatrics* 2005;116(3):753-755.

## Citations and Reference Literature: Folic Acid

- Brent RL, Godfrey P, Oakley GP Jr. Triumph and/or tragedy: the present Food and Drug Administration program of enriching grains with folic acid. *Pediatrics* 2006;117:930-932. (Editorial)
- Brevik A, Vollset SE, Tell GS, et al. Plasma concentration of folate as a biomarker for the intake of fruit and vegetables: the Hordaland Homocysteine Study. *Am J Clin Nutr* 2005;81(2):434-439.
- Brigden ML. A systematic approach to macrocytosis: sorting out the causes. *Postgrad Med* 1995;97(5):171-172, 175-177, 181-184 passim.
- Bronstrup A, Hages M, Prinz-Langenohl R, et al. Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy young women. *Am J Clin Nutr* 1998;68:1104-1110.
- Brosnan JT. Homocysteine and cardiovascular disease: interactions between nutrition, genetics and lifestyle. *Can J Appl Physiol* 2004;29(6):773-780.
- Brouwer IA, van Dusseldorp M, Thomas CMG, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. *Am J Clin Nutr* 1999;69:99-104.
- Brouwer IA, van Dusseldorp M, West CE, et al. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. *J Nutr* 1999;129(6):1135-1139.
- Buccianti G, Bamonti Catena F, Patrosso C, et al. Reduction of the homocysteine plasma concentration by intravenously administered folinic acid and vitamin B(12) in uraemic patients on maintenance haemodialysis. *Am J Nephrol* 2001;21(4):294-299.
- Buckley DI, McPherson RS, North CQ, et al. Dietary micronutrients and cervical dysplasia in Southwestern American Indian women. *Nutr Cancer* 1992;17(2):179-185.
- Budd GT, Herzog P, Bukowski RM. Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. *Invest New Drugs* 1994;12(4):283-287.
- Bugge JF. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. *J Intern Med* 1996;240(4):249-251.
- Buist RA. Drug-nutrient interactions: an overview. *Int Clin Nutr Rev* 1984;4(3):114. (Review)
- Bunout D, Petermann M, Hirsch S, et al. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. *Nutrition* 2000;16(6):434-438.
- Busby A, Abramsky L, Dolk H, et al. Preventing neural tube defects in Europe: population based study. *BMJ* 2005;330(7491):574-575.
- Butterworth CE Jr. Effect of folate on cervical cancer: synergism among risk factors. *Ann N Y Acad Sci* 1992;669:293-299.
- Butterworth CE Jr, Bendich A. Folic acid and the prevention of birth defects. *Annu Rev Nutr* 1996;16:73-97.
- Butterworth CE Jr, Hatch KD, Gore H, et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. *Am J Clin Nutr* 1982;35(1):73-82.
- Butterworth CE Jr, Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. *JAMA* 1992;267(4):528-533.
- Butterworth CE, Hatch KD, Mueller H, et al. Folate-induced regression of cervical intraepithelial neoplasia (CIN) in users of oral contraceptive agents (OCA). *Am J Clin Nutr* 1980;33:926.
- Butterworth CE Jr, Hatch KD, Soong SJ, et al. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. *Am J Obstet Gynecol* 1992;166:803-809.
- Butterworth CE Jr, Tamura T. Folic acid safety and toxicity: a brief review. *Am J Clin Nutr* 1989;50:353-358.
- Callaghan TJ. The effect of folic acid on seborrheic dermatitis. *Cutis* 1967;3:583-588.
- Campbell NRC. How safe are folic acid supplements? *Arch Intern Med* 1996;156:1638-1644.
- Camilo E, Zimmerman J, Mason JB, et al. Folate synthesized by bacteria in the human upper small intestine is assimilated by the host. *Gastroenterology* 1996;110(4):991-998.
- Campbell AK, Jagust WJ, Mungas DM, et al. Low erythrocyte folate, but not plasma vitamin B-12 or homocysteine, is associated with dementia in elderly Latinos. *J Nutr Health Aging* 2005;9(1):39-43.
- Carl GF, Hudson FZ, McGuire BS Jr. Phenytoin-induced depletion of folate in rats originates in liver and involves a mechanism that does not discriminate folate form. *J Nutr* 1997;127(11):2231-2238.
- Carrero JJ, Lopez-Huertas E, Salmeron LM, et al. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. *J Nutr* 2005;135(6):1393-1399.
- Caspary WF. Biguanides and intestinal absorptive function. *Acta Hepatogastroenterol* 1977;24:473-480.
- Caudill MA, Bailey LB, Gregory JF III. Consumption of the folate breakdown product para-aminobenzoylglutamate contributes minimally to urinary folate catabolite excretion in humans: investigation using [(13)C(5)]para-aminobenzoylglutamate. *J Nutr* 2002;132(9):2613-2616.
- Cembrowski GS, Zhang MM, Prosser CI, et al. Folate is not what it is cracked up to be. *Arch Intern Med* 1999;159:2747-2748.

## Citations and Reference Literature: Folic Acid

- Chadwick D. Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies. *Epilepsia* 1997;38(Suppl 9):S16-20.
- Charlton KE, Kolbe-Alexander TL, Nel JH. Development of a novel nutrition screening tool for use in elderly South Africans. *Public Health Nutr* 2005;8(5):468-479.
- Chen L, Guo XB, Deng FR, et al. [Study on the relationship between methylene tetrahydrofolate reductase gene (677C→T) mutation and skin lesions in endemic arsenic poisoning] *Wei Sheng Yan Jiu* 2005;34(2):146-148. [Chinese]
- Chen M, Xia B, Rodriguez-Gueant RM, et al. Genotypes 677TT and 677CT+1298AC of methylenetetrahydrofolate reductase are associated with the severity of ulcerative colitis in central China. *Gut* 2005;54(5):733-734.
- Child DF, Hudson PR, Jones H, et al. The effect of oral folic acid on glutathione, glycaemia and lipids in type 2 diabetes. *Diabetes Nutr Metab* 2004;17(2):95-102.
- Chiuve SE, Giovannucci EL, Hankinson SE, et al. Alcohol intake and methylenetetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine. *Am J Clin Nutr* 2005;82(1):155-162.
- Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. *J Nutr* 2000;130(2):129-132.
- Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. *Am J Gastroenterol* 2000;95(12):3498-3502.
- Chu E, Drake JC, Boarman D, et al. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. *J Biol Chem* 1999;265:8470-8478.
- Chung JS, Haque R, Guha Mazumder DN, et al. Blood concentrations of methionine, selenium, beta-carotene, and other micronutrients in a case-control study of arsenic-induced skin lesions in West Bengal, India. *Environ Res* 2006;101(2):230-237.
- Clark DW, Donnelly E, Coulter DM, et al. Linking pharmacovigilance with pharmacogenetics. *Drug Safety* 2004;27(15):1171-1184.
- Clarke R. Vitamin B12, folic acid, and the prevention of dementia. *N Engl J Med* 2006;354:2817-2819. (Editorial)
- Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12 and serum homocysteine levels in confirmed Alzheimer's disease. *Arch Neurol* 1998;11:1449-1455.
- Collins CS, Bailey LB, Hillier S, et al. Red blood cell uptake of supplemental folate in patients on anticonvulsant drug therapy. *Am J Clin Nutr* 1988;48(6):1445-1450.
- Comella P, Casaretti R, De Vita F, et al. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. *Ann Oncol* 1999;10(8):915-921.
- Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection. *J Affect Disord* 1989;16(2-3):103-107.
- Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. *J Psychopharmacol* 2005;19(1):59-65. (Review)
- Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection. *J Affect Disord* 1989;16:103-107.
- Coronato A, Glass GB. Depression of the intestinal uptake of radio-vitamin B 12 by cholestyramine. *Proc Soc Exp Biol Med* 1973;142(4):1341-1344.
- Corrada MM, Kawas CH, Hallfrisch J, et al. Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging. *Alzheimer's Dementia* 2005;1(1):11-18.
- Coulthard SA, Matheson EC, Hall AG, et al. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. *Nucleosides Nucleotides Nucleic Acids* 2004;23(8-9):1385-1391. (Review)
- Cravo M. Alcohol, methylenetetrahydrofolate 677C→T genotype, and low folate intake: concurrent causes for hyperhomocysteinemia. *Am J Clin Nutr* 2005;82:3-4. (Editorial)
- Cravo ML, Albuquerque CM, Salazar de Sousa L, et al. Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. *Am J Gastroenterol* 1998;93(11):2060-2064.
- Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders: clinical potential. *Drugs* 45(5):623-636, 1993.
- Crittenden RG, Martinez NR, Playne MJ. Synthesis and utilisation of folate by yoghurt starter cultures and probiotic bacteria. *Int J Food Microbiol* 2003;80(3):217-222.
- Cronstein BN. Pharmacogenetics in the rheumatic diseases. *Ann Rheum Dis* 2004;63(Suppl 2):ii25-ii27. (Review)
- Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptual vitamin supplementation. *N Engl J Med* 1992;327:1832-1835.
- Czeizel AE, Timar L, Sarkozi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. *Pediatrics* 1999;104:e66.
- Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. *Teratology* 1996;53:345-351.

## Citations and Reference Literature: Folic Acid

- Cuskelly GJ, McNulty H, Scott JM. Fortification with low amounts of folic acid makes a significant difference in folate status in young women: implications for the prevention of neural tube defects. *Am J Clin Nutr* 1999;70(2):234-239.
- Cutolo M, Sulli A, Pizzorni C, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. *Ann Rheum Dis* 2001;60(8):729-735. (Review)
- Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. *JAMA* 1995;274:1698-1702.
- Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. *Am J Gastroenterol* 2005;100(4):886-895.
- Davies JF II, Delcamp TJ, Prendergast NJ, et al. Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. *Biochemistry* 1990;29:9467-9479.
- Davis RE. Clinical chemistry of folic acid. *Adv Clin Chem* 1986;25:233-294.
- Davis SR, Quinlivan EP, Shelnutt KP, et al. Homocysteine synthesis is elevated but total remethylation is unchanged by the methylenetetrahydrofolate reductase 677C→T polymorphism and by dietary folate restriction in young women. *J Nutr* 2005;135(5):1045-1050.
- Davis SR, Quinlivan EP, Shelnutt KP, et al. The methylenetetrahydrofolate reductase 677C→T polymorphism and dietary folate restriction affect plasma one-carbon metabolites and red blood cell folate concentrations and distribution in women. *J Nutr* 2005;135(5):1040-1044.
- Davis SR, Stacpoole PW, Williamson J, et al. Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. *Am J Physiol Endocrinol Metab* 2004;286(2):E272-279.
- Dawson TA. Aciclovir in herpes simplex gingivostomatitis: folic acid may be beneficial in aphthous stomatitis. *BMJ* 1997;315(7116):1162. (Letter)
- de Bree A, Verschuren WM, Blom HJ, et al. Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20-65 y. *Am J Clin Nutr* 2001;73(6):1027-1033.
- de Luis DA, Fernandez N, Arranz ML, et al. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. *J Diabetes Complications* 2005;19(1):42-46.
- Dedoussis GV, Panagiotakos DB, Pitsavos C, et al. An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease. *Int J Cardiol* 2005;100(3):409-414.
- DeFronzo RA, Goodman A, Metformin Investigator Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. *N Engl J Med* 1995;333:541-549.
- Deleu D, Louon A, Sivagnanam S, et al. Long-term effects of nitrous oxide anaesthesia on laboratory and clinical parameters in elderly Omani patients: a randomized double-blind study. *J Clin Pharm Ther* 2000;25:271-277.
- den Heijer M, Brouwer IA, Bos GM. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. *Arterioscler Thromb Vasc Biol* 1998;18:356-361.
- Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost* 2005;3(2):292-299.
- Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. *Kidney Int Suppl* 1996;57:S11-S17.
- Desouza C, Keebler M, McNamara DB, et al. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. *Drugs* 2002;62(4):605-616. (Review)
- Devlin AM, Clarke R, Birks J, et al. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. *Am J Clin Nutr* 2006;83:708-713.
- Devlin AM, Ling EH, Peerson JM, et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. *Hum Mol Genet* 2000;9:2837-2844.
- Devuyst O, Goffin E, Pirson Y, et al. Creatinine rise after fibrate therapy in renal graft recipients. *Lancet* 1993;341:840. (Letter)
- Dierkes J, Kroesen M, Pietrzik K. Folic acid and vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. *Int J Vitam Nutr Res* 1998;68:98-103.
- Dijkmans BA. Folate supplementation and methotrexate. *Br J Rheumatol* 1995;34(12):1172-1174. (Review)
- Dingle B. Pharmacogenomics in oncology: emerging insights into the impact of genetic variability on cancer care. *Oncology Exchange* 2004;3(5):8-11. (Review)
- Dodelson de Kremer R, Gross C. Maternal mutation 677C→T in the methylenetetrahydrofolate reductase gene associated with severe brain injury in offspring. *Clin Genet* 2005;67(1):69-80.
- Doshi S, McDowell I, Moat S, et al. Folate improves endothelial function in patients with coronary heart disease. *Clin Chem Lab Med* 2003;41(11):1505-1512.

## Citations and Reference Literature: Folic Acid

- Ducloux D, Aboubakr A, Motte G, et al. Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. *Nephrol Dial Transplant* 2002;17(5):865-870.
- Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. *Curr Opin Lipidol* 1997;8(1):28-34. (Review)
- Duhra P, Hodgson C, Martin JA, et al. Intestinal folate absorption in methotrexate treated psoriatic patients. *Br J Dermatol* 1988;119(3):327-332.
- Durga J, Anteunis LJ, Schouten EG, et al. Association of folate with hearing is dependent on the 5,10-methylenetetrahydrofolate reductase 677C→T mutation. *Neurobiol Aging* 2006;27(3):482-489.
- Durga J, Bots ML, Schouten EG, et al. Low concentrations of folate, not hyperhomocysteinemia, are associated with carotid intima-media thickness. *Atherosclerosis* 2005;179(2):285-292.
- Durga J, van Boxtel MP, Schouten EG, et al. Folate and the methylenetetrahydrofolate reductase 677C→T mutation correlate with cognitive performance. *Neurobiol Aging* 2006;27(2):334-343.
- Durga J, van Tits LJ, Schouten EG, et al. Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial. *Arch Intern Med* 2005;165(12):1388-1394.
- Durga J, Verhoef P, Anteunis LJC, et al. Effects of folic acid supplementation on hearing in older adults: a randomized, controlled trial. *Ann Intern Med* 2007;146(1):1-9.
- Durga J, Verhoef P, Bots ML, et al. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. *Atherosclerosis* 2004;176(1):1-19. (Review)
- Ebbesen LS. Hyperhomocysteinemia, thrombosis and vascular biology. *Cell Mol Biol (Noisy-le-grand)* 2004;50(8):917-930.
- Ebly EM, Schaefer JP, Campbell NR, et al. Folate status, vascular disease and cognition in elderly Canadians. *Age Ageing* 1998;27(4):485-491.
- Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-634.
- Eichholzer M, Luthy J, Moser U, et al. Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. *Swiss Med Weekly* 2001;131(37-38):539-549. (Review)
- Elias MF, Robbins MA, Budge MM, et al. Homocysteine, folate, and vitamins B6 and B12 blood levels in relation to cognitive performance: the Maine-Syracuse study. *Psychosom Med* 2006;68(4):547-554.
- Elias MF, Sullivan LM, D'Agostino RB, et al. Homocysteine and cognitive performance in the Framingham offspring study: age is important. *Am J Epidemiol* 2005;162(7):644-653.
- Elliott P, Stamler J, Dyer AR, et al. Association between protein intake and blood pressure: the INTERMAP Study. *Arch Intern Med* 2006;166:79-87.
- Elmazar MM, Thiel R, Nau H. Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice. *Fundam Appl Toxicol* 1992;18(3):389-394.
- Elsborg L. Vitamin B12 and folic acid in Crohn's disease. *Dan Med Bull* 1982;29:362-365.
- Endres M, Ahmadi M, Kruman I, et al. Folate deficiency increases postischemic brain injury. *Stroke* 2005;36(2):321-325.
- Endresen GK, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis: an update and proposals for guidelines. *Scand J Rheumatol* 2001;30(3):129-134. (Review)
- Erb N, Kitas GD. Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients. *Rheumatology* 2001;40(6):715-716.
- Erbe RW. Inborn errors of folate metabolism. In: Blakely R, Whitehead V, eds. *Folates and pterins*. New York: John Wiley; 1986:413-465.
- Erbe RW. Inborn errors of folate metabolism (second of two parts). *N Engl J Med* 1975;293:807-812.
- Eskes TK. Open or closed? A world of difference: a history of homocysteine research. *Nutr Rev* 1998;56(8):236-244.
- Eussen SJPM, de Groot LCPGM, Clarke R, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. *Arch Intern Med* 2005;165:1167-1172.
- Fang X, Namba H, Akamine S, et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with cerebral hemorrhage. *Neurol Res* 2005;27(1):73-76.
- Farmer JA, Gotto AM Jr. Antihyperlipidaemic agents: drug interactions of clinical significance. *Drug Safety* 1994;11(5):301-309.
- Farmer JA, Gotto AM Jr. Choosing the right lipid-regulating agent: a guide to selection. *Drugs* 1996;52(5):649-661.
- Fava M, Borus JS, Alpert JE, et al. Folate, vitamin B12, and homocysteine in major depressive disorder. *Am J Psychiatry* 1997;154(3):426-428.
- Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. *Mutat Res* 2001;475(1-2):57-67. (Review)

## Citations and Reference Literature: Folic Acid

- Fenech M, Baghurst P, Luderer W, et al. Low intake of calcium, folate, nicotinic acid, vitamin E, retinol, beta-carotene and high intake of pantothenic acid, biotin and riboflavin are significantly associated with increased genome instability: results from a dietary intake and micronucleus index survey in South Australia. *Carcinogenesis* 2005;26(5):991-999.
- Fernandez-Miranda C, Yebra M, Aranda JL, et al. Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease. *Int J Cardiol* 2007;118(3):345-349.
- Ferraroni M, La Vecchia C, D'Avanzo B, et al. Selected micronutrient intake and the role of colon cancer. *Br J Cancer* 1994;70:1150-1155.
- Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia? *Aust Fam Phys* 2003;32:383-384.
- Fiorina P, Lanfredini M, Montanari A, et al. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. *Am J Hypertens* 1998;11(9):1100-1107.
- Fiskerstrand T, Ueland PM, Refsum H. Folate depletion induced by methotrexate affects methionine synthase activity and its susceptibility to inactivation by nitrous oxide. *J Pharmacol Exp Ther* 1997;282(3):1305-1311.
- Fitchie JG, Comer RW, Hanes PJ, Reeves GW. The reduction of phenytoin-induced gingival overgrowth in a severely disabled patient: a case report. *Compendium* 1989;10(6):314, 317-320.
- Flicker L, Ames D. Metabolic and endocrinological causes of dementia. *Int Psychogeriatr* 2005;17(Suppl 1):S79-S92.
- Flouvier B, Devulder B. Folic acid, xanthine oxidase, and uric acid. *Ann Intern Med* 1978;88:269. (Letter)
- Flynn MA, Irvin W, Krause G. The effect of folate and cobalamin on osteoarthritic hands. *J Am Coll Nutr* 1994;13(4):351-356.
- Food and Nutrition Board, Institute of Medicine. Folic acid: dietary reference intakes: thiamin, riboflavin, niacin, vitamin B-6, vitamin B-12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press; 1998:193-305.
- Forman JP, Rimm EB, Stampfer MJ, et al. Folate intake and the risk of incident hypertension among US women. *JAMA* 2005;293(3): 320-329.
- Fransen J, Laan RF, Van Der Laar MA, et al. Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis. *Ann Rheum Dis* 2004;63(10):1222-1226.
- Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and "schizophrenia": a defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. *N Engl J Med* 1975;292:491-496.
- Freudenheim JL, Graham S, Marshall JR, et al. Folate intake and carcinogenesis of the colon and rectum. *Int J Epidemiol* 1991;20(2): 368-374.
- Friso S, Girelli D, Trabetti E, et al. The MTHFR 1298A>C polymorphism and genomic DNA methylation in human lymphocytes. *Cancer Epidemiol Biomarkers Prev* 2005;14(4):938-943.
- Friso S, Jacques PF, Wilson PW, et al. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. *Circulation* 2001;103(23):2788-2791.
- Froscher W, Maier V, Laage M, et al. Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. *Clin Neuropharmacol* 1995;18:165-182.
- Fry DW, Jackson RC. Biological and biochemical properties of new anticancer folate antagonists. *Cancer Metastasis Rev* 1987;5(3): 251-270. (Review)
- Fuchs CS, Willett WC, Colditz GA, et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. *Cancer Epidemiol Biomarkers Prev* 2002;11(3):227-234.
- Fujii K, Golivan JH, Huennekens FM. Activation of methionine synthetase: further characterisation of the flavoprotein system. *Arch Biochem Biophys* 1977;178:662-670.
- Gamble MV, Ahsan H, Liu X, et al. Folate and cobalamin deficiencies and hyperhomocysteinemia in Bangladesh. *Am J Clin Nutr* 2005;81:1372-1377.
- Gamble MV, Liu X, Ahsan H, et al. Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. *Am J Clin Nutr* 2006;84(5):1093-1101.
- Gamble MV, Liu X, Ahsan H, et al. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. *Environ Health Perspect* 2005;113(12):1683-1688.
- Ganji V, Kafai MR. Frequent consumption of milk, yogurt, cold breakfast cereals, peppers, and cruciferous vegetables and intakes of dietary folate and riboflavin but not vitamins B-12 and B-6 are inversely associated with serum total homocysteine concentrations in the US population. *Am J Clin Nutr* 2004;80(6):1500-1507.
- Gaume V, Mougin F, Figard H, et al. Physical training decreases total plasma homocysteine and cysteine in middle-aged subjects. *Ann Nutr Metab* 2005;49(2):125-131.
- Gerhard GT, Duell PB. Homocysteine and atherosclerosis. *Curr Opin Lipidol* 1999;10(5):417-428.
- Ghadirian AM, Ananth J, Engelmann F. Folic acid deficiency and depression. *Psychosomatics* 1980;21(11):926-929.

## Citations and Reference Literature: Folic Acid

- Gibberd FB, Nicholls A, Wright MG. The influence of folic acid on the frequency of epileptic attacks. *Eur J Clin Pharmacol* 1981;19:57-60.
- Giovannucci E, Rimm EB, Ascherio A, et al. Alcohol, low-methionine: low-folate diets, and risk of colon cancer in men. *J Natl Cancer Inst* 1995;87(4):265-273.
- Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. *J Natl Cancer Inst* 1993;85:875-884.
- Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate and colon cancer in women in the nurses' health study. *Ann Intern Med* 1998;129:517-524.
- Glade MJ. Workshop on folate, B12, and choline: sponsored by the Panel on Folate and other B Vitamins of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, Washington, D.C., March 3-4, 1997. *Nutrition* 1999;15:92-96.
- Glynn SA, Albane D, Pietinen P, et al. Colorectal cancer and folate status: a nested case-control study among male smokers. *Cancer Epidemiol Biomarkers Prev* 1996;5:487-494.
- Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. *Lancet* 1990;336(8712):392-395.
- Golbahar J, Fathi Z, Tamadon M. Distribution of 5,10-methylenetetrahydrofolate reductase (C667T) polymorphism and its association with red blood cell 5-methyltetrahydrofolate in the healthy Iranians. *Clin Nutr* 2005;24(1):83-87.
- Gomez G. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. *Gastroenterology* 1991;100(6):1789-1790.
- Gong K, Zhang Z, Sun X, et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. *Am Heart J* 2006;151(1):62-68.
- Gonin JM. Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease. *Curr Opin Nephrol Hypertens* 2005;14(3):277-281.
- Gori AM, Corsi AM, Fedi S, et al. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. *Am J Clin Nutr* 2005;82:335-341.
- Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. *Circulation* 2002;106(19):2510-2513. (Review)
- Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? *Circulation* 2002;106(18):2404-2408. (Review)
- Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. *JAMA* 1997;277:1775-1781.
- Gregory JF III. Case study: folate bioavailability. *J Nutr* 2001;131:1376S-1382S.
- Gueant-Rodriguez R-M, Gueant J-L, Debard R, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. *Am J Clin Nutr* 2006;83:701-707.
- Guenther BD, Sheppard CA, Tran P, et al. The structure and properties of methylenetetrahydrofolate reductase from *Escherichia coli* suggest how folate ameliorates human hyperhomocysteinemia. *Nature Struct Biol* 1999;6:359-365.
- Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. *Ann Rheum Dis* 1999;58(2):79-84.
- Handy DE, Loscalzo J. Homocysteine and atherothrombosis: diagnosis and treatment. *Curr Atheroscler Rep* 2003;5(4):276-283. (Review)
- Handy DE, Zhang Y, Loscalzo J. Homocysteine downregulates cellular glutathione peroxidase (GPx1) by decreasing translation. *J Biol Chem* 2005;280(16):15518-15525.
- Hankey GJ, Eikelboom JW, Loh K, et al. Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population. *Cerebrovasc Dis* 2005;19(2):110-116.
- Hannon-Fletcher MP, Armstrong NC, Scott JM, et al. Determining bioavailability of food folates in a controlled intervention study. *Am J Clin Nutr* 2004;80(4):911-918.
- Hansen DK, Grafton TF, Dial SL, et al. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. *Teratology* 1995;52(5):277-285.
- Harper JM, Levine AJ, Rosenthal DL, et al. Erythrocyte folate levels, oral contraceptive use and abnormal cervical cytology. *Acta Cytol* 1994;38(3):324-330.
- Hasegawa Y. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy] *Gan To Kagaku Ryoho* 2003;30(3):325-333. (Review) [Japanese]
- Hartman M, van Ede A, Severens JL, et al. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. *J Rheumatol* 2004;31(5):902-908.
- Hathcock JN. Metabolic mechanisms of drug-nutrient interactions. *Fed Proc* 1985;44(1 Pt 1):124-129. (Review)

## Citations and Reference Literature: Folic Acid

- Hathcock JN. Vitamin and mineral safety. 2nd ed. Washington, DC: Council for Responsible Nutrition; 2004. (Review)
- Hayes C, Werler MM, Willett WC, et al. Case-control study of periconceptional folic acid supplementation and oral clefts. *Am J Epidemiol* 1996;143:1229-1234.
- Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. *Cardiovasc Drugs Ther* 2002;16:391-399.
- He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke. *Lancet* 2006;367:320-326. (Meta-analysis)
- Heimberger DC. Localized deficiencies of folic acid in aerodigestive tissues. *Ann N Y Acad Sci* 1992;669:87-96.
- Heimburger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: report of a preliminary randomized, double-blind intervention trial. *JAMA* 1988;259:1525-1530.
- Hendler SS, Rorvik DR, eds. PDR for nutritional supplements. Montvale, NJ: Medical Economics Company, Inc; 2001. (Review)
- Herbert V. Folic acid. In: Shils M, Olson JA, Shike M, et al, eds. Modern nutrition in health and disease. 9th ed. Baltimore: Williams and Wilkins; 1999:433-446.
- Herbert V, Colman N, Spivack M, et al. *Am J Obstet Gynecol* 1975;123(2):175-179.
- Herrmann M, Muller S, Kindermann I, et al. Plasma B vitamins and their relation to the severity of chronic heart failure. *Am J Clin Nutr* 2007;85(1):117-124.
- Hertrampf E, Cortes F, Erickson JD, et al. Consumption of folic acid-fortified bread improves folate status in women of reproductive age in Chile. *J Nutr* 2003;133(10):3166-3169.
- Heseker H, Kubler W, Pudel V, et al. Psychological disorders as early symptoms of a mild-moderate vitamin deficiency. *Ann N Y Acad Sci* 1992;669:352-357.
- Hickling S, Hung J, Knuiman M, et al. Impact of voluntary folate fortification on plasma homocysteine and serum folate in Australia from 1995 to 2001: a population based cohort study. *J Epidemiol Community Health* 2005;59(5):371-376.
- Hirakawa K, Aoshima M, Hiraku Y, et al. Photohydrolysis of methotrexate produces pteridine, which induces poly-G-specific DNA damage through photoinduced electron transfer. *Photochem Photobiol* 2002;76(5):467-472.
- Hirsch S, Ronco AM, Vasquez M, et al. Hyperhomocysteinemia in healthy young men and elderly men with normal serum folate concentration is not associated with poor vascular reactivity or oxidative stress. *J Nutr* 2004;134(7):1832-1835.
- Hodges R. Drug-nutrient interaction. In: Nutrition in medical practice. Philadelphia: Saunders; 1980:323-331.
- Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. *JAMA* 1995;273(23):1849-1854.
- Holick CN, De Vivo I, Feskanich D, et al. Intake of fruits and vegetables, carotenoids, folate, and vitamins A, C, E and risk of bladder cancer among women (United States). *Cancer Causes Control* 2005;16(10):1135-1145.
- Holmes VA, Wallace JM, Alexander HD, et al. Homocysteine is lower in the third trimester of pregnancy in women with enhanced folate status from continued folic acid supplementation. *Clin Chem* 2005;51(3):629-634.
- Holt GA. Food and drug interactions. Chicago: Precept Press; 1998. (Review)
- Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *Br Med J* 1998;316:894-898.
- Hong SY, Yang DH, Chang SK. Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. *Am J Nephrol* 1998;18(5):367-372.
- Hopkins PN, Wu LL, Wu J, et al. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. *Arterioscler Thromb Vasc Biol* 1995;15:1314-1320.
- Hortobagyi GN, Yap HY, Blumenschein GR, et al. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. *Cancer* 1983;51(5):769-772.
- Houghton LA, Green TJ, Donovan UM, et al. Association between dietary fiber intake and the folate status of a group of female adolescents. *Am J Clin Nutr* 1997;66(6):1414-1421.
- Houghton LA, Sherwood KL, Pawlosky R, et al. [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. *Am J Clin Nutr* 2006;83: 842-850.
- Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. *Am J Clin Nutr* 1999;69:564-571.
- Howe RB, Branda RF, Douglas SD, et al. Hereditary dyserythropoiesis with abnormal membrane folate transport. *Blood* 1979;54:1080-1090.
- Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2-diabetes mellitus. *Drug Safety* 1999;20:489-503.
- Huemer M, Fodinger M, Huemer C, et al. Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study. *Clin Exp Rheumatol* 2003;21(2):249-255.

## Citations and Reference Literature: Folic Acid

- Huemer M, Huemer C, Ulmer H, et al. No evidence for hyperhomocysteinemia or increased prevalence of genetic polymorphisms in the homocysteine pathway in patients with moderate juvenile idiopathic arthritis. *J Rheumatol* 2005;32(1):170-174.
- Husemoen LL, Thomsen TF, Fenger M, Jorgensen T. Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype: Inter99 (7). *Eur J Clin Nutr* 2004;58(8):1142-1150.
- Hussien MM, McNulty H, Armstrong N, et al. Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients. *Br J Cancer* 2005;92(8):1524-1530.
- Hustad S, Ueland PM, Vollset SE. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. *Clin Chem* 2000;46:1065-1071.
- Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. *Circ Res* 2002;90(1):21-28. (Review)
- Iivanainen M, Savolainen H. Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy. *Acta Neurol Scand Suppl* 1983;97:49-67.
- Irizarry MC, Gurol ME, Raju S, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. *Neurology* 2005;65(9):1402-1408.
- Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. *Am J Hum Genet* 2000;67(4):986-990.
- Jackman AL, Judson IR. The new generation of thymidylate synthase inhibitors in clinical study. *Exp Opin Invest New Drugs* 1996;5:719-736.
- Jacob RA. Folate, DNA methylation, and gene expression: factors of nature and nurture. *Am J Clin Nutr* 2000;72:903-904.
- Jacques PF, Kalmbach R, Bagley PJ. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. *J Nutr* 2002;132:283-288.
- Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340(19):1449-1454.
- Janinis J, Papakostas P, Samelis G, et al. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. *Ann Oncol* 2000;11(2):163-167.
- Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates: exploitation for folate-based chemotherapy and immunotherapy. In: Jackman AL, ed. *Antifolate drugs in cancer therapy*. Totowa, NJ: Humana Press; 1999:293-321.
- Jiang Q, Chen K, Ma X, et al. Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. *Cancer Detect Prev* 2005;29(2):146-154.
- Johansson M, Witthoft CM, Bruce A, et al. Study of wheat breakfast rolls fortified with folic acid: the effect on folate status in women during a 3-month intervention. *Eur J Nutr* 2002;41(6):279-286.
- Joober R, Benkelfat C, Lal S, et al. Association between the methylenetetrahydrofolate reductase 677CT missense mutation and schizophrenia. *Mol Psychiatry* 2000;5:323-326.
- Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? *J Gerontol A Biol Sci Med Sci* 1997;52:M76-M79.
- Joosten E, Pelemans W. Megaloblastic anaemia in an elderly patient treated with triamterene. *Neth J Med* 1991;38(5-6):209-211.
- Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. *Acta Derm Venereol (Stockh)* 1997;77:460-462.
- Kado DM, Karlamangla AS, Huang MH, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. *Am J Med* 2005;118(2):161-167.
- Kamath AF, Chauhan AK, Kisucka J, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. *Blood* 2006;107(2):591-593.
- Kamen B. Folate and antifolate pharmacology. *Semin Oncol* 1997;24(5 Suppl 18):S18-30-S18-39. (Review)
- Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. *Circulation* 2006;114(25):2788-2797.
- Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. *Arch Intern Med* 1989;149:2501-2503.
- Kato I, Dnistriant AM, Schwartz M, et al. Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. *Br J Cancer* 1999;79(11-12):1917-1922.
- Kato I, Dnistriant AM, Schwartz M, et al. Epidemiologic correlates of serum folate and homocysteine levels among users and non-users of vitamin supplement. *Int J Vitam Nutr Res* 1999;69(5):322-329.

## Citations and Reference Literature: Folic Acid

- Kauwell GP, Wilsky CE, Cerda JJ, et al. Methylenetetrahydrofolate reductase mutation (677C→T) negatively influences plasma homocysteine response to marginal folate intake in elderly women. *Metabolism* 2000;49(11):1440-1443.
- Kavey R-EW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2006;114:2710-2738.
- Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. *Br J Cancer* 1998;78(Suppl 3):1-7. (Review)
- Kelly CB, McDonnell AP, Johnston TG, et al. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. *J Psychopharmacol* 2004;18(4):567-571.
- Kim SM, Kim YK, Hann S-K. Serum levels of folic acid and vitamin B12 in Korean patients with vitiligo. *Yonsei Med J* 1999;40:195-198.
- Kim Y-I. Folate and cancer prevention: a new medical application of folate beyond hyperhomocysteinemia and neural tube defects. *Nutr Rev* 1999;57:314-321.
- Kim Y-I. Folate and carcinogenesis: evidence, mechanisms, and implications. *J Nutr Biochem* 1999;10:66-88.
- Kim Y-I. Methyltetrahydrofolate reductase polymorphisms, folate and cancer risk: a paradigm of gene-nutrient interactions in carcinogenesis. *Nutr Rev* 2000;58:205-209.
- Kim YI, Baik HW, Fawaz K, et al. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. *Am J Gastroenterol* 2001;96(1):184-195.
- Kim Y, Mason JB. Folate, epithelial dysplasia and colon cancer. *Proc Assoc Am Physicians* 1995;107(2):218-227. (Review)
- Kim Y-I, Shirwadkar S, Choi S-W, et al. Effects of dietary folate on DNA strand breaks within mutation-prone exons of the p53 gene in the rat colon. *Gastroenterol* 2000;199(1):151-161.
- Kinder AJ, Hassell AB, Brand J, et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. *Rheumatology* 2005;44(1):61-66.
- Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine versus vitamin B12 and folate. *Clin Chem* 2000;46(8B):1277-1283.
- Klerk M, Durga J, Schouten EG, et al. No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in older adults. *Thromb Haemost* 2005;94(1):96-100.
- Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA* 2002;288(16):2023-2031.
- Klipstein FA, Schenk EA, Samloff IM. Folate repletion associated with oral tetracycline therapy in tropical sprue. *Gastroenterology* 1966;51(3):317-332.
- Klipstein FA, Samloff IM. Folate synthesis by intestinal bacteria. *Am J Clin Nutr* 1966;19(4):237-246.
- Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. *Blood* 2003;101(7):2483-2488.
- Kluijtmans LA, Whitehead AS. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk. *Eur Heart J* 2001;22(4):294-299.
- Knock E, Deng L, Qing Wu Q, et al. Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c. *Cancer Res* 2006;66:10349-10356.
- Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. *Med Toxicol* 1987;2(1):10-32.
- Koda-Kimble MA, Guglielmo BJ, Young LL, et al, eds. *Applied therapeutics: the clinical use of drugs*. Philadelphia: Lippincott Williams & Wilkins; 2004.
- Kornberg A, Segal R, Theitler J, et al. Folic acid deficiency, megaloblastic anemia and peripheral polyneuropathy due to oral contraceptives. *Isr J Med Sci* 1989;25(3):142-145.
- Kremer JM, Bigaouette J. Nutrient intake of patients with rheumatoid arthritis is deficient in pyridoxine, zinc, copper, and magnesium. *J Rheumatol* 1996;23(6):990-994.
- Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. *J Neurosci* 2002;22(5):1752-1762.
- Kuhn W, Hummel T, Woitalla D, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. *Neurology* 2001;56(2):281-282.
- Kunugi H, Fukuda R, Hattori M, et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. *Mol Psychiatry* 1998;3:435-7.

## Citations and Reference Literature: Folic Acid

- Kut V, Patel JD, Argiris A. Pemetrexed: a novel antifolate agent enters clinical practice. *Expert Rev Anticancer Ther* 2004;4(4):511-522. (Review)
- Kwasniewska A, Tukendorf A, Semczuk M. Folate deficiency and cervical intraepithelial neoplasia. *Eur J Gynaecol Oncol* 1997;18(6): 526-530.
- Lairon D, Arnault N, Bertrais S, et al. Dietary fiber intake and risk factors for cardiovascular disease in French adults. *Am J Clin Nutr* 2005;82:1185-1194.
- Lambie DG, Johnson RH. Drugs and folate metabolism. *Drugs* 1985;30(2):145-155.
- Lamers Y, Prinz-Langenohl R, Bramswig S, et al. Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age. *Am J Clin Nutr* 2006;84:156-161.
- Lamers Y, Prinz-Langenohl R, Moser R, et al. Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. *Am J Clin Nutr* 2004;79(3):473-448.
- Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. *J Intern Med* 1995;237(4):381-388.
- Laohavinij S, Wedge SR, Lind MJ, et al. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. *Invest New Drugs* 1996;14(3):325-335.
- Larsson SC, Hakansson N, Giovannucci E, et al. Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. *J Natl Cancer Inst* 2006;98(6):407-413.
- Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. *J Cancer Res Clin Oncol* 1993;119:549-554.
- Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis: a case-control study. *Gastroenterology* 1989;97(2):255-259.
- Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. *Gastroenterology* 1997;112(1):29-32.
- Laurence KM, James N, Miller MH, et al. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. *Br Med J (Clin Res Ed)* 1981;282(6275):1509-1511.
- Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003;326:1423.
- Lawrence JM, Watkins ML, Chiu V, et al. Do racial and ethnic differences in serum folate values exist after food fortification with folic acid? *Am J Obstet Gynecol* 2006;194(2):520-526.
- Lerner V, Kanevsky M, Dwolatzky T, et al. Vitamin B12 and folate serum levels in newly admitted psychiatric patients. *Clin Nutr* 2006;25(1):60-67.
- Lewis DP, Van Dyke DC, Stumbo PJ, et al. Drug and environmental factors associated with adverse pregnancy outcomes: part I: antiepileptic drugs, contraceptives, smoking, and folate. *Ann Pharmacother* 1998;32(7-8):802-817. (Review)
- Lewis DP, Van Dyke DC, Stumbo PJ, et al. Drug and environmental factors associated with adverse pregnancy outcomes: part II: improvement with folic acid. *Ann Pharmacother* 1998;32(9):947-961. (Review)
- Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? *BMJ* 2005;331(7524):1053. (Meta-analysis)
- Li M, Chen J, Li YS, et al. Folic acid reduces adhesion molecules VCAM-1 expression in aortic of rats with hyperhomocysteinemia. *Int J Cardiol* 2006;106(2):285-288.
- Li CL, Werner P, Cohen G. Lipid peroxidation in brain: interactions of L-DOPA/dopamine with ascorbate and iron. *Neurodegeneration* 1995;4(2):147-153. Erratum in *Neurodegeneration* 1995;4(3):347.
- Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: results of the Goes extension study. *Heart* 2005;91(9):1213-1214. (Letter)
- Lievers KJ, Boers GH, Verhoeof P, et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. *J Mol Med* 2001;79(9):522-528.
- Lin P-T, Lee B-J, Chang H-H, et al. Low-dose folic acid supplementation reduces homocysteine concentration in hyperhomocysteinemic coronary artery disease patients. *Nutr Res* 2006;26(9):460-466.
- Lindenbaum J. Drugs and vitamin B12 and folate metabolism. *Curr Concepts Nutr* 1983;12:73-87. (Review)
- Lindenbaum J, Roman MJ. Nutritional anemia in alcoholism. *Am J Clin Nutr* 1980;33(12):2727-2735.
- Lipkin GW, Tomson CRV. Severe reversible renal failure with bezafibrate. *Lancet* 1993;341:371. (Letter)
- Liu T, Soong SJ, Wilson NP, et al. A case control study of nutritional factors and cervical dysplasia. *Cancer Epidemiol Biomarkers Prev* 1993;2(6):525-530.

## Citations and Reference Literature: Folic Acid

- Lobo A, Naso A, Arheart K, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. *Am J Cardiol* 1999;83(6):821-825.
- Lokk J. [Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency: patients with Parkinson disease run the risk of elevated homocysteine levels] *Lakartidningen* 2003;100(35):2674-2677. (Review) [Swedish]
- Longstreth GF, Green R. Folate levels in inflammatory bowel disease. *N Engl J Med* 1982;306(24):1488. (Letter)
- Lonn E, Held C, Arnold JM, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006;354(15):1567-1577.
- Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. *N Engl J Med* 2006;354(15):1629-1632. (Editorial)
- Loscalzo J. Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. *Circulation* 2001;104(10):1086-1088. (Editorial)
- Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. *N Engl J Med* 2006;354(15):1629-1632. (Editorial)
- Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. *J Clin Invest* 1996;98:5-7.
- Loscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. *Epilepsia* 2006;47(8):1253-1284. (Review)
- Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. *Mol Genet Metab* 2000;71:121-138.
- Lucock M, Yates Z. Folic acid: vitamin and panacea or genetic time bomb? *Natl Rev Genet* 2005;6(3):235-240. (Review)
- Luther L, Santini R, Brewster C, et al. Folate binding by insoluble components of American and Puerto Rican diets. *Ala J Med Sci* 1965;2(4):389-393.
- Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res* 1997;57(6):1098-1102.
- MacKenzie JF, Russell RI. The effect of pH on folic acid absorption in man. *Clin Sci Mol Med* 1976;51(4):363-368.
- MacKenzie KE, Wiltshire EJ, Gent R, et al. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. *Pediatrics* 2006;118(1):242-253.
- Makoff R. Vitamin replacement therapy in renal failure patients. *Miner Electrolyte Metab* 1999;25(4-6):349-351. (Review)
- Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. *Oncologist* 2002;7:288-323. (Review)
- Malinow MR, Boston AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* 1999;99(1):178-182.
- Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N Engl J Med* 1998;338:1009-1015.
- Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. *Cochrane Database Syst Rev* 2003;(4):CD004514. (Review)
- Mangoni AA, Sherwood RA, Swift CG, et al. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. *J Intern Med* 2002;252:497-503.
- Maron BA, Loscalzo J. Homocysteine. *Clin Lab Med* 2006;26(3):591-609, vi.
- Marsh S, King CR, Ahluwalia R, et al. Distribution of ITPA P32T alleles in multiple world populations. *J Hum Genet* 2004;49(10):579-581.
- Martinez JJ, Ruiz FA, Candil SD. Baseline serum folate level may be a predictive factor of weight loss in a morbid-obesity-management programme. *Br J Nutr* 2006;96(5):956-964.
- Martinez ME, Giovannucci E, Jiang R, et al. Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. *Int J Cancer* 2006;119(6):1440-1446.
- Martinez O, Roe DA. Effect of oral contraceptives on blood folate levels in pregnancy. *Am J Obstet Gynecol* 1977;128:255-261.
- Marz R. Medical nutrition from Marz. 2nd ed. Portland, OR; Omni Press; 1997. (Review)
- Mason JB. Folate and colonic carcinogenesis: searching for a mechanistic understanding. *J Nutr Biochem* 1994;5:170-175.
- Mason JB. Folate status: effects on carcinogenesis. In: Bailey LB, ed. *Folates in health and disease*. New York: Marcel Dekker, 1995:361-378.
- Mason P. Dietary supplements. London: Pharmaceutical Press; 2001. (Review)
- Mathers JC. Reversal of DNA hypomethylation by folic acid supplements: possible role in colorectal cancer prevention. *Gut* 2005;54(5):579-581. (Editorial)
- Matsui MS, Rozovski SJ. Drug-nutrient interaction. *Clin Ther* 1982;4(6):423-440. (Review)

## Citations and Reference Literature: Folic Acid

- Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. *Pharmacogenomics* 2002;3:485-492.
- Mauritz R, Peters GJ, Priest DG, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. *Biochem Pharmacol* 2002;63(2):105-115.
- Mayer O Jr, Simon J, Holubec L, et al. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. *Eur J Clin Pharmacol* 2003;59(5-6):367-371.
- Mayer O Jr, Simon J, Holubec L, et al. Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients. *Eur J Cardiovasc Prev Rehabil* 2004;11(3):244-249.
- Mayer O Jr, Simon J, Rosolova H, et al. The effects of folate supplementation on some coagulation parameters and oxidative status surrogates. *Eur J Clin Pharmacol* 2002;58(1):1-5.
- McKillip DJ, McNulty H, Scott JM, et al. The rate of intestinal absorption of natural food folates is not related to the extent of folate conjugation. *Am J Clin Nutr* 2006;84:167-173.
- McLaughlin WS, Ball DE, Seymour RA, et al. The pharmacokinetics of phenytoin in gingival crevicular fluid and plasma in relation to gingival overgrowth. *J Clin Periodontol* 1995;22(12):942-945.
- McLean RR, Karasik D, Selhub J, et al. Association of a common polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene with bone phenotypes depends on plasma folate status. *J Bone Miner Res* 2004;19(3):410-418.
- McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. *Pharmacogenomics* 2002;3:89-98.
- McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. *N Engl J Med* 2006;354:2764-2772.
- McNulty H, Cuskelly GJ, Ward M. Response of red blood cell folate to intervention: implications for folate recommendations for the prevention of neural tube defects. *Am J Clin Nutr* 2000;71(5 Suppl):1308S-1311S.
- McNulty H, Dowey LC, Scott JM. Riboflavin supplementation lowers plasma homocysteine in individuals homozygous for the MTHFR C677T polymorphism. *J Inherited Metab Dis* 2003;26(Suppl 1):12.
- McNulty H, McKinley MC, Wilson B. Impaired function of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. *Am J Clin Nutr* 2002;76:436-441.
- Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991;338:131-137.
- Melse-Boonstra A, Holm PI, Ueland PM, et al. Betaine concentration as a determinant of fasting total homocysteine concentrations and the effect of folic acid supplementation on betaine concentrations. *Am J Clin Nutr* 2005;81:1378-1382.
- Mendelsohn LG, Gates SB, Habeck LL, et al. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. *Adv Enzyme Regul* 1996;36:365-381.
- Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle-aged adults. *Am J Epidemiol* 1993;138:225-236.
- Meyer RE, Oakley GP Jr. Folic acid fortification. *Lancet* 1999;354:2168. (Letter)
- Milano G, McLeod HL. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? *Eur J Cancer* 2000;36:37-42.
- Miller JW. Assessing the association between vitamin B-12 status and cognitive function in older adults. *Am J Clin Nutr* 2006;84:1259-1260.
- Mills JL. Fortification of foods with folic acid-how much is enough? *N Engl J Med* 2000;342:1442-1445.
- Mills JL, McPartlin P, Kirke PM, et al. Homocysteine metabolism in pregnancies complicated by neural tube defects. *Lancet* 1995;345:149-151.
- Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA* 1989;262:2847-2852.
- Miriuka SG, Langman LJ, Evrovski J, et al. Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients. *Transplant Int* 2005;18(1):29-35.
- Moat SJ, Ashfield-Watt PA, Powers HJ, et al. Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype. *Clin Chem* 2003;49(2):295-302.
- Moat SJ, Clarke ZL, Madhavan AK, et al. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. *Eur J Pharmacol* 2006;530(3):250-258.
- Moat SJ, Doshi SN, Lang D, et al. Treatment of coronary heart disease with folic acid: is there a future? *Am J Physiol Heart Circ Physiol* 2004;287(1):H1-7. (Editorial, Review)
- Moat SJ, Hill MH, McDowell IF, et al. Reduction in plasma total homocysteine through increasing folate intake in healthy individuals is not associated with changes in measures of antioxidant activity or oxidant damage. *Eur J Clin Nutr* 2003;57(3):483-489.

## Citations and Reference Literature: Folic Acid

- Moat SJ, Madhavan A, Taylor SY, et al. High- but not low-dose folic acid improves endothelial function in coronary artery disease. *Eur J Clin Invest* 2006;36(12):850-859.
- Moghadasian MH, et al. Homocysteine and coronary artery disease. *Arch Intern Med* 1997;157:2299-2308.
- Molloy AM, Daly S, Mills JL, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red cell folates: implications for folate intake recommendations. *Lancet* 1997;349:1591-1593.
- Monji A, Yanagimoto K, Maekawa T, et al. Plasma folate and homocysteine levels may be related to interictal "schizophrenia-like" psychosis in patients with epilepsy. *J Clin Psychopharmacol* 2005;25(1):3-5.
- Montes LF, Diaz ML, Lajous J, et al. Folic acid and vitamin B12 in vitiligo: a nutritional approach. *Cutis* 1992;50:39-42.
- Morel CF, Duncan AM, Desilets V. A fragile site at 10q23 (FRA10A) in a phenytoin-exposed fetus: a case report and review of the literature. *Prenat Diagn* 2005;25(4):318-321.
- Morgan SL, Baggott JE, Alarcon GS. Methotrexate and sulfasalazine combination therapy: is it worth the risk? *Arthritis Rheum* 1993;36(2):281-282.
- Morgan S, Baggott J, Vaughn W, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. *Ann Intern Med* 1994;121:833-841.
- Morgan SL, Oster RA, Lee JY, et al. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. *Arthritis Rheum* 2004;50(10):3104-3111.
- Morris MC, Evans DA, Bienias JL, et al. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. *Arch Neurol* 2005;62:641-645.
- Mouzas IA, Papavassiliou E, Koutroubakis I. Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. *Ital J Gastroenterol Hepatol* 1998;30(4):421-425. (Review)
- Moyers S, Bailey LB. Fetal malformations and folate metabolism: review of recent evidence. *Nutr Rev* 2001;59(7):215-224. (Review)
- Muller T, Werne B, Fowler B, et al. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. *Lancet* 1999;354(9173):126-7.
- Muller T, Woitalla D, Fowler B, et al. 3-OMD and homocysteine plasma levels in Parkinsonian patients. *J Neural Transm* 2002;109(2):175-179.
- Muntjewerff JW, Hoogendoorn ML, Kahn RS, et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. *Am J Med Genet B Neuropsychiatr Genet* 2005;135(1):69-72.
- Murphy JV, Thome LM, Michals K, et al. Folic acid responsive rages, seizures and homocystinuria. *J Inherited Metab Dis* 1985;8:109-110.
- Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. *Annu Rev Med* 2003;54:437-452. (Review)
- Naurath HJ, Joosten E, Riezler R, et al. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. *Lancet* 1995;346:85-89.
- Navarro Silvera SA, Jain M, Howe GR, et al. Dietary folate consumption and risk of ovarian cancer: a prospective cohort study. *Eur J Cancer Prev* 2006;15(6):511-515.
- Nelen WL, Blom HJ, Steegers EA, et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. *Fertil Steril* 2000;74(6):1196-1199.
- Nelen WL, Blom HJ, Steegers EA, et al. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. *Obstet Gynecol* 2000;95(4):519-524.
- Nelen WLDM, Van der Molen EF, Blom HJ, et al. Recurrent early pregnancy loss and genetic related disturbances in folate and homocysteine metabolism. *Br J Hosp Med* 1997;58:511-513.
- Neuhouser ML, Beresford SA, Hickok DE, et al. Absorption of dietary and supplemental folate in women with prior pregnancies with neural tube defects and controls. *J Am Coll Nutr* 1998;17(6):625-630.
- Nilsson-Ehle H. Age-related changes in cobalamin (vitamin B12) handling: implications for therapy. *Drugs Aging* 1998;12:277-292.
- Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration and its relation to symptoms of vascular disease in psychogeriatric patients. *Dementia Geriatr Cogn Disord* 2005;20(1):35-41.
- Nirmalan N, Sims PF, Hyde JE. Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors. *Mol Biochem Parasitol* 2004;136(1):63-70.
- Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. *Mol Cancer Ther* 2002;1(7):545-552.
- Norlund L, Grubb A, Fex G, et al. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. *Clin Chem Lab Med* 1998;36(3):175-178.

## Citations and Reference Literature: Folic Acid

- Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997;337:230-236.
- O'Keeffe ST. Restless legs syndrome: a review. *Arch Intern Med* 1996;156:243-248.
- O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. *Arch Neurol* 2004;61(6):865-868.
- Oakley GP Jr. Eat right and take a multivitamin. *N Engl J Med* 1998;338:1060-1061. (Editorial)
- Oakley GP Jr, Adams MJ, Dickinson CM. More folic acid for everyone, now. *J Nutr* 1996;126(3):751S-755S.
- Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. *Epilepsy Res* 1991;8(1):75-78.
- Olivares AB, Bernal MJ, Ros G, et al. [Quality of data on folic acid content in vegetables included in several Spanish Food Composition Tables and new data on their folate content] *Nutr Hosp* 2006;21(1):97-108. (Review) [Spanish]
- Olszewski AJ, Szostak WB, Bialkowska M, et al. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. *Atherosclerosis* 1989;75(1):1-6.
- Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. *J Rheumatol* 1998;25(1):36-43.
- Oster KA. Evaluation of serum cholesterol reduction and xanthine oxidase inhibition in the treatment of atherosclerosis. *Recent Adv Stud Cardiac Struct Metab* 1973;3:73-80.
- O'Shaughnessy JA. Pemetrexed: an active new agent for breast cancer. *Semin Oncol* 2002;29(6 Suppl 18):57-62. (Review)
- O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. *Arch Neurol* 2004;61(6):865-868.
- Palazzi C, D'Amico E, Pennese E, et al. Normalization of methotrexate-induced high levels of serum transaminases after ursodeoxycholic acid administration in a rheumatoid arthritis patient. *Rheumatology* 2003;42(10):1266-1267.
- Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. *J Clin Psychiatry* 2004;65(8):1090-1095.
- Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. *J Clin Psychiatry* 2004;65(8):1096-1098.
- Papoutsakis C, Yiannakouris N, Manios Y, et al. Plasma homocysteine concentrations in Greek children are influenced by an interaction between the methylenetetrahydrofolate reductase C677T genotype and folate status. *J Nutr* 2005;135(3):383-388.
- Papoutsakis C, Yiannakouris N, Manios Y, et al. The effect of MTHFR(C677T) genotype on plasma homocysteine concentrations in healthy children is influenced by gender. *Eur J Clin Nutr* 2006;60(2):155-162.
- Passeri M, Cucinotta D, Abate G, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. *Aging (Milano)* 1993;5(1):63-71.
- Paulionis L, Kane SL, Meckling KA. Vitamin status and cognitive function in a long-term care population. *BMC Geriatr* 2005;5(1):16.
- Pearson H. Pervasive vitamin fortification could alter genes. *Nature* 2005.
- Pentieva K, McNulty H, Reichert R, et al. The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men. *J Nutr* 2004;134(3):580-585.
- Perry TL, Applegarth DA, Evans ME, et al. Metabolic studies of a family with massive formiminoglutamic aciduria. *Pediatr Res* 1975;9:117-122.
- Pfeiffer CM, Caudill SP, Gunter EW, et al. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. *Am J Clin Nutr* 2005;82(2):442-450.
- Pietarinen GJ, Leichter J, Pratt RF. Dietary folate intake and concentration of folate in serum and erythrocytes in women using oral contraceptives. *Am J Clin Nutr* 1977;30(3):375-380.
- Pironi L, Cornia GL, Ursitti MA, et al. [Prevalence and pathogenesis of folate deficiency in patients with quiescent or clinically mildly active Crohn disease]. *Minerva Dietol Gastroenterol* 1987;33(4):307-313. [Italian]
- Potena L, Grigioni F, Magnani G, et al. Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease. *Clin Nutr* 2002;21(3):245-248.
- Prasad AS, Lei KY, Moghissi KS, et al. Effect of oral contraceptives on nutrients: III: vitamins B6, B12, and folic acid. *Am J Obstet Gynecol* 1976;125(8):1063-1069.
- Prasad K. Homocysteine, a risk factor for cardiovascular disease. *Int J Angiol* 1999;8(1):76-86.
- Prichard MN, Prichard LE, Shipman C Jr. Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir. *Antiviral Res* 1993;20(3):249-259.
- Pronsky Z. Powers and Moore's food-medication interactions. 9th ed. Pottstown, PA: Food-Medication Interactions, 1991. (Review)

## Citations and Reference Literature: Folic Acid

- Pullin CH, Ashfield-Watt PA, Burr ML, et al. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype. *J Am Coll Cardiol* 2001;38(7):1799-1805.
- Pullin CH, Wilson JF, Ashfield-Watt PA, et al. Influence of methylenetetrahydrofolate reductase genotype, exercise and other risk factors on endothelial function in healthy individuals. *Clin Sci (Lond)* 2002;102(1):45-50.
- Puto K, Garey JS. Pemetrexed therapy for malignant pleural mesothelioma. *Ann Pharmacother* 2005;39(4):678-683.
- Quadri P, Fragiocomo C, Pezzati R, et al. Homocysteine and B vitamins in mild cognitive impairment and dementia. *Clin Chem Lab Med* 2005;43(10):1096-1100.
- Quere I, Perneger TV, Zittoun J, et al. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. *Lancet* 2002;359(9308):747-752.
- Quinlivan EP, Davis SR, Shelton KP, et al. Methylenetetrahydrofolate reductase 677C→T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynucleosides. *J Nutr* 2005;135(3):389-396.
- Racek J, Rusnakova H, Trefil L, et al. The influence of folate and antioxidants on homocysteine levels and oxidative stress in patients with hyperlipidemia and hyperhomocysteinemia. *Physiol Res* 2005;54(1):87-95.
- Ramos MI, Allen LH, Haan MN, et al. Plasma folate concentrations are associated with depressive symptoms in elderly Latina women despite folic acid fortification. *Am J Clin Nutr* 2004;80(4):1024-1028.
- Ramos MI, Allen LH, Mungas DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. *Am J Clin Nutr* 2005;82(6):1346-1352.
- Rampersaud GC, Bailey LB, Kauwell GP. Relationship of folate to colorectal and cervical cancer: review and recommendations for practitioners. *J Am Diet Assoc* 2002;102(9):1273-1282. (Review)
- Rampersaud GC, Kauwell GP, Bailey LB. Folate: a key to optimizing health and reducing disease risk in the elderly. *J Am Coll Nutr* 2003;22(1):1-8. (Review)
- Rampersaud GC, Kauwell GP, Hutson AD, et al. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. *Am J Clin Nutr* 2000;72(4):998-1003.
- Rath HC, Caesar I, Roth M, et al. Nutritional deficiencies and complications in chronic inflammatory bowel diseases. *Med Klin* 93(1):6-10;1998.
- Ravaglia G, Forti P, Maioli F, et al. Folate, but not homocysteine, predicts the risk of fracture in elderly persons. *J Gerontol A Biol Sci Med Sci* 2005;60(11):1458-1462.
- Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. *Am J Clin Nutr* 2005;82(3):636-643.
- Ray MS, Muggia FM, Leichman CG, et al. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. *J Natl Cancer Inst* 1993;85(14):1154-1159.
- Refaai TM, Al-Salem IH, Nkansa-Dwamena D, et al. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. *Clin Rheumatol* 2002;21(6):457-461.
- Regland B, Germgard T, Gottfries CG, et al. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. *J Neural Transm* 1997;104:931-941.
- Regland B, Johansson BV, Grenfeldt B, et al. Homocysteinemia is a common feature of schizophrenia. *J Neural Transm Gen Sect* 1995;100:165-169.
- Reynolds EH. Effects of folic acid on the mental state and fit frequency of drug treated epileptic patients. *Lancet* 1967;1:1086.
- Reynolds EH, Milner G, Matthews DM, et al. Anticonvulsant therapy, megaloblastic haemopoiesis and folic acid metabolism. *QJM* 1966;35:521-537.
- Riddell LJ, Chisholm A, Williams S, et al. Dietary strategies for lowering homocysteine concentrations. *Am J Clin Nutr* 2000;71(6):1448-1454.
- Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. *JAMA* 1998;279(5):359-364.
- Robbins MA, Elias MF, Budge MM, et al. Homocysteine, type 2 diabetes mellitus, and cognitive performance: the Maine-Syracuse Study. *Clin Chem Lab Med* 2005;43(10):1101-1106.
- Robinson C, Weigly E. Basic nutrition and diet therapy. New York: MacMillan; 1984. (Review)
- Roe DA. Diet and drug interactions. New York: Van Nostrand Reinhold; 1989. (Review)
- Roe DA. Drug-induced nutritional deficiencies. 2nd ed. Westport, CT: Avi Publishing; 1985:158-159. (Review)
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. Drugs and nutrients: the interactive effects. New York: Marcel Decker; 1984:505-523. (Review)

## Citations and Reference Literature: Folic Acid

- Rohan TE, Jain MG, Howe GR, et al. Dietary folate consumption and breast cancer risk. *J Natl Cancer Inst* 2000;92:266-269.
- Rosenberg IH. Absorption and malabsorption of folates. *Clin Haematol* 1976;5(3):589-618. (Review)
- Rosenberg LE, Fenton WA. Disorders of propionate and methylmalonate metabolism. In: Scriver C, Beaudet A, Sly W, et al, eds. *Metabolic basis of inherited disease*. New York: McGraw-Hill; 1989:821-844.
- Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. *Proc Natl Acad Sci U S A* 1996;93:15227-15232.
- Rossmann JA, Ingles E, Brown RS. Multimodal treatment of drug-induced gingival hyperplasia in a kidney transplant patient. *Compendium* 1994;15(10):1266, 1268-1270, 1272-1274.
- Russell RM. A minimum of 13,500 deaths annually from coronary artery disease could be prevented by increasing folate intake to reduce homocysteine levels. *JAMA* 1996;275:1828-1829.
- Sakuta H, Suzuki T, Yasuda H, et al. Plasma vitamin B(12), folate and homocysteine levels in gastrectomized men. *Clin Nutr* 2005;24(2):244-249.
- Sanderson P, McNulty H, Mastroiacovo P, et al. Folate bioavailability: UK Food Standards Agency workshop report. *Br J Nutr* 2003;90(2):473-479. (Review)
- Santhosh-Kumar CR, Bisping JS, Kick SD, et al. Folate sufficient subjects do not accumulate additional folates during supplementation. *Am J Hematol* 2000;64:71-72.
- Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecabalamin on hip fractures in patients with stroke: a randomized controlled trial. *JAMA* 2005;293(9):1082-1088.
- Sato Y, Honda Y, Iwamoto J, et al. Homocysteine as a predictive factor for hip fracture in stroke patients. *Bone* 2005;36(4):721-726.
- Savage DG, Lindenbaum J. Folate-cobalamin interactions. In: Bailey LB, ed. *Folate in health and disease*. New York: Marcel Dekker, Inc; 1995:237-285.
- Savage DG, Lindenbaum J, Stabler SP, et al. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. *Am J Med* 1994;96(3):239-246.
- Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. *J Clin Oncol* 2003;21(8):1556-1561.
- Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. *Am J Clin Nutr* 2000;71(5 Suppl):1295S-1303S.
- Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. *JAMA* 2002;288:973-979.
- Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001;345(22):1593-1600.
- Schorah CJ, Devitt H, Lucock M, et al. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. *Eur J Clin Nutr* 1998;52(6):407-411.
- Schroder H, Clausen N, Ostergard E, et al. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. *Pediatr Hematol Oncol* 1986;3:241-247.
- Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinaemia in an elderly population. *JAMA* 1993;270:2693-2698.
- Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. *Epidemiology* 2001;12(4):420-428.
- Semenza JC, Delfino RJ, Ziogas A, et al. Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. *Breast Cancer Res Treat* 2003;77(3):217-223.
- Senti FR, Pilch SM. Analysis of folate data from the second National Health and Nutrition Examination Survey (NHANES II). *J Nutr* 1985;115:1398-1402.
- Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002;346(7):476-483.
- Seshadri N, Robinson K. Homocysteine, B vitamins, and coronary artery disease. *Med Clin North Am* 2000;84(1):215-237.
- Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. *J Clin Periodontol* 1996;23(3 Pt 1):165-175. (Review)
- Shafer RB, Nuttall FQ. Calcium and folic acid absorption in patients taking anticonvulsant drugs. *J Clin Endocrinol Metab* 1975;41(06):1125-1129.
- Shane B. Folic acid, vitamin B-12, and vitamin B-6. In: Stipanuk M, ed. *Biochemical and physiological aspects of human nutrition*. Philadelphia: Saunders; 2000:483-518.

## Citations and Reference Literature: Folic Acid

- Shaw GM, Lammer EJ, Wasserman CR, et al. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. *Lancet* 1995;345:393-396.
- Shaw GM, O'Malley CD, Wasserman CR, et al. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. *Am J Med Genet* 1995;59:536-545.
- Shelnutt KP, Kauwell GP, Chapman CM, et al. Folate status response to controlled folate intake is affected by the methylenetetrahydrofolate reductase 677C→T polymorphism in young women. *J Nutr* 2003;133(12):4107-4111.
- Shelnutt KP, Kauwell GP, Gregory JF III, et al. Methylenetetrahydrofolate reductase 677C→T polymorphism affects DNA methylation in response to controlled folate intake in young women. *J Nutr Biochem* 2004;15(9):554-560.
- Sheu WH, Chin HM, Lee WJ, et al. Prospective evaluation of folic acid supplementation on plasma homocysteine concentrations during weight reduction: a randomized, double-blinded, placebo-controlled study in obese women. *Life Sci* 2005;76(18):2137-2145.
- Sherwood KL, Houghton LA, Tarasuk V, et al. One-third of pregnant and lactating women may not be meeting their folate requirements from diet alone based on mandated levels of folic acid fortification. *J Nutr* 2006;136(11):2820-2826.
- Shiroky JB. Folic acid and methotrexate in rheumatoid arthritis. *Ann Intern Med* 1996;124(1 Pt 1):73-74. (Letter)
- Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. *Arthritis Rheum* 1993;36:795.
- Shrubsole MJ, Jin F, Dai Q, et al. Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. *Cancer Res* 2001;61:7136-7141.
- Shrubsole MJ, Shu XO, Ruan ZX, et al. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study. *Breast Cancer Res Treat* 2005;91(1):73-79.
- Silaste ML, Rantala M, Alfthan G, et al. Plasma homocysteine concentration is decreased by dietary intervention. *Br J Nutr* 2003;89(3):295-301.
- Silaste ML, Rantala M, Sampi M, et al. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. *J Nutr* 2001;131:2643-2647.
- Sim E, Pinter K, Mushtaq A, et al. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. *Biochem Soc Trans* 2003;31(Pt 3):615-619. (Review)
- Skibola CF, Forrest MS, Coppede F, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. *Blood* 2004;104(7):2155-2162.
- Skibola CF, Smith MT, Hubbard A, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. *Blood* 2002;99(10):3786-3791.
- Slattery ML, Potter JD, Samowitz W, et al. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. *Cancer Epidemiol Biomarkers Prev* 1999;8(6):513-518.
- Smith AD. Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12. *Am J Clin Nutr* 2007;85(1):3-5. (Editorial)
- Smith DB, Racusen LC. Folate metabolism and the anticonvulsant efficacy of phenobarbital. *Arch Neurol* 1973;28(1):18-22.
- Smithells RW, Seller MJ, Harris R, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. *Lancet* 1983;1:1027-1031.
- Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. *Arch Dis Child* 1976;51(12):944-950.
- Smulders YM, Rakic M, Slaats EH, et al. Fasting and post-methionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. *Diabetes Care* 1999;22:125-132.
- Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. *Arch Intern Med* 1999;159:1289-1298. (Review)
- Snowdon DA, Tully CL, Smith CD, et al. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. *Am J Clin Nutr* 2000;71(4):993-998.
- Sohn KJ, Smirnakis F, Moskovitz DN, et al. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. *Gut* 2004;53(12):1825-1831.
- Solini A, Santini E, Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. *Int J Obes (Lond)* 2006;30(8):1197-1202.
- Song J, Sohn KJ, Medline A, et al. Chemopreventive effects of dietary folate on intestinal polyps in *Apc*+/−*Msh2*−/− mice. *Cancer Res* 2000;60(12):3191-3199.
- Soon SY, Ansari A, Yaneza M, et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2004;16(9):921-926.
- Sosin M, Handa S. Lesson of the week: low dose methotrexate and bone marrow suppression. *BMJ* 2003;326(7383):266-267.

## Citations and Reference Literature: Folic Acid

- Spence JD, Bang H, Chambliss LE, et al. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. *Stroke* 2005;36(11):2404-2409.
- Spijkerman AM, Smulders YM, Kostense PJ, et al. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn Study. *Arterioscler Thromb Vasc Biol* 2005;25(4):778-784.
- Stabler SP, Allen RH, Fried LP, et al. Racial differences in prevalence of cobalamin and folate deficiencies in disabled elderly women. *Am J Clin Nutr* 1999;70:911-919.
- Stahl Z, Belmaker RH, Friger M, et al. Nutritional and life style determinants of plasma homocysteine in schizophrenia patients. *Eur Neuropsychopharmacol* 2005;15(3):291-295.
- Stam F, van Guldener C, Ter Wee PM, et al. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. *Kidney Int* 2005;67(1):259-264.
- Stanford JL, Molina H, Phillips J, et al. Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease. *Cardiovasc Surg* 2000;8(7):567-571.
- Stanger O, Semmelrock HJ, Wonisch W, et al. Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. *J Pharmacol Exp Ther* 2002;303(1):158-162.
- Stark KD, Pawlosky RJ, Bebblo S, et al. Status of plasma folate after folic acid fortification of the food supply in pregnant African American women and the influences of diet, smoking, and alcohol consumption. *Am J Clin Nutr* 2005;81:669-677.
- Steegers-Theunissen RP. Folate metabolism and neural tube defects: a review. *Eur J Obstet Gynecol Reprod Biol* 1995;61(1):39-48. (Review)
- Steffen LM. Eat your fruit and vegetables. *Lancet* 2006;367:278-279. (Editorial)
- Steffen LM, Folsom AR, Cushman M, et al. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism. *The Longitudinal Investigation of Thromboembolism Etiology*. *Circulation* 2007;115(2):188-195.
- Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease. *Arch Intern Med* 1998;158:1301-1306.
- Steinberg SC, Steinberg AD. Phenytoin-induced gingival overgrowth control in severely retarded children. *J Periodontol* 1982;53(7):429-433.
- Stevens VL, Rodriguez C, Pavlack AL, et al. Folate nutrition and prostate cancer incidence in a large cohort of US men. *Am J Epidemiol* 2006;163(11):989-996.
- Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Am J Clin Nutr* 2006;83(4):895-904.
- Stolzenberg-Solomon RZ, Pietinen P, Barrett MJ, et al. Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers. *Am J Epidemiol* 2001;153:680-687.
- Stoney CM, Engebretson TO. Plasma homocysteine concentrations are positively associated with hostility and anger. *Life Sci* 2000;66:2267-2275.
- Stott DJ, Macintosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. *Am J Clin Nutr* 2005;82(6):1320-1326.
- Strain JJ, Dowey L, Ward M, et al. B-vitamins, homocysteine metabolism and CVD. *Proc Nutr Soc* 2004;63(4):597-603.
- Strohle A, Wolters M, Hahn A. Folic acid and colorectal cancer prevention: molecular mechanisms and epidemiological evidence. *Int J Oncol* 2005;26(6):1449-1464. (Review)
- Stumm W, Morgan JJ, eds. Aquatic chemistry: an introduction emphasizing chemical equilibria in natural waters. 2nd ed. New York, NY: Wiley; 1981:240.
- Su LJ, Arab L. Nutritional status of folate and colon cancer risk: evidence from NHANES I epidemiologic follow-up study. *Ann Epidemiol* 2001;11(1):65-72.
- Suitor CW, Bailey LB. Dietary folate equivalents: interpretation and application. *J Am Diet Assoc* 2000;100(1):88-94.
- Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. *Hum Genet* 2002;111(4-5):360-367.
- Sunder-Plassmann G, Fodinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. *J Am Soc Nephrol* 2000;11:1106-1116.
- Susser E, Brown AS, Klonowski E, et al. Schizophrenia and impaired homocysteine metabolism: a possible association. *Biol Psychiatry* 1998;44:141-143.
- Swain RA, St Clair L. The role of folic acid in deficiency states and prevention of disease. *J Fam Pract* 1997;44(2):138-144.
- Tamura T, Picciano MF. Folate and human reproduction. *Am J Clin Nutr* 2006;83:993-1016. (Review)
- Tardif JC, Gregoire J, Lavoie MA, et al. Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies. *Curr Opin Lipidol* 2003;14(6):615-620. (Review)

## Citations and Reference Literature: Folic Acid

- Taylor EC. Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents. *Adv Exp Med Biol* 1993;338:387-408. (Review)
- Taylor MJ, Carney SM, Goodwin GM, et al. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. *J Psychopharmacol* 2004;18(2):251-256. (Review)
- Taylor MJ, Geddes J. Folic acid as ultimate in disease prevention: folate also improves mental health. *BMJ* 2004;328(7442):768-769. (Letter)
- Terry P, Jain M, Miller AB, et al. Dietary intake of folic acid and colorectal cancer risk in a cohort of women. *Int J Cancer* 2002;97(6):864-867.
- The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006;354(15):1567-1577.
- Thorpe SJ, Sands D, Heath AB, et al. An international standard for whole blood folate: evaluation of a lyophilised haemolysate in an international collaborative study. *Clin Chem Lab Med* 2004;42(5):533-539.
- Threlkeld DS, ed. Antineoplastics, antimetabolites, methotrexate. In: *Facts and Comparisons drug information*. St Louis: Facts and Comparisons; 1990:653-654.
- Threlkeld DS, ed. Central nervous system drugs, antidepressants, monoamine oxidase inhibitors. In: *Facts and Comparisons drug information*. St Louis: Facts and Comparisons; 1997. (Review)
- Threlkeld DS, ed. Gastrointestinal drugs, sulfasalazine. In: *Facts and Comparisons drug information*. St Louis: Facts and Comparisons; 1997. (Review)
- Threlkeld DS, ed. Hormones, oral contraceptives. In: *Facts and Comparisons drug information*. St Louis: Facts and Comparisons; 1994. (Review)
- Till U, Röhl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. *Atherosclerosis* 2005;181(1):131-135.
- Title LM, Cummings PM, Giddens K, et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. *J Am Coll Cardiol* 2000;36:758-765.
- Tjonneland A, Christensen J, Olsen A, et al. Folate intake, alcohol and risk of breast cancer among postmenopausal women in Denmark. *Eur J Clin Nutr* 2006;60(2):280-286.
- Tolarova M. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. *Lancet* 1982;ii:217. (Letter)
- Tolmunen T, Hintikka J, Voutilainen S, et al. Association between depressive symptoms and serum concentrations of homocysteine in men: a population study. *Am J Clin Nutr* 2004;80(6):1574-1578.
- Tomkin GH, Hadden DR, Weaver JA, et al. Vitamin-B12 status of patients on long-term metformin therapy. *BMJ* 1971;2:685-687.
- Toole JF, Malinow MR, Chambliss LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004;291:565-575.
- Torres OA, Miller VS, Buist NM, et al. Folinic acid-responsive neonatal seizures. *J Child Neurol* 1999;14:529-532.
- Trinh BN, Ong CN, Coetzee GA, et al. Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. *Hum Genet* 2002;111(3):299-302.
- Troen AM. The central nervous system in animal models of hyperhomocysteinemia. *Prog Neuropsychopharmacol Biol Psychiatry* 2005;29(7):1140-1151. (Review)
- Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. *Am Fam Physician* 1991;44(5):1651-1658. (Review)
- Truswell AS. ABC of nutrition: nutrition for pregnancy. *Br Med J (Clin Res Ed)* 1985;291(6490):263-266.
- Tse A, Brigle K, Taylor SM, et al. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. *J Biol Chem* 1998;273(40):25953-25960.
- Tucker KL, Olson B, Bakun P, et al. Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial. *Am J Clin Nutr* 2004;79(5):805-811.
- Tucker KL, Qiao N, Scott T, et al. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. *Am J Clin Nutr* 2005;82(3):627-635.
- Tuckerman M, Turco S. Human nutrition. Philadelphia: Lea and Febiger; 1983:215-222.
- Ubbink JB, van der Merwe A, Vermaak WJ, et al. Hyperhomocysteinemia and the response to vitamin supplementation. *Clin Invest* 1993;71(12):993-998.
- Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocysteinemia. *Am J Clin Nutr* 1993;57:47-53.

## Citations and Reference Literature: Folic Acid

- Ueland PM, Refsum H. [Plasma homocysteine, a risk factor for premature vascular disease: plasma levels in healthy persons; during pathologic conditions and drug therapy] Nord Med 1989;104(11):293-298. [Norwegian]
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS-34). Lancet 1998;352:854-865.
- Ulrich CM, Bigler J, Bostick R, et al. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 2002;62:3361-3364.
- Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9(12):1381-1385.
- Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3(12): 912-920. (Review)
- Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism: a promising direction. Pharmacogenomics 2002;3:299-313.
- USDA: Composition of foods: USDA handbook #8. Washington, DC: ARS, USDA; 1976-1986.
- van Baak MA, Visscher TLS. Public health success in recent decades may be in danger if lifestyles of the elderly are neglected. Am J Clin Nutr 2006;84:1259-1260. (Editorial)
- van der Put NM, van Straaten HW, Trijbels FJ, et al. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med 2001;226:243-270.
- van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41(6):658-665.
- van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44(11):2525-2530.
- van Ede AE, Laan RF, De Abreu RA, et al. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2002;61(12):1060-1064.
- Van Guelpen B, Hultdin J, Johansson I, et al. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke 2005;36(7):1426-1431.
- van Meurs JB, Uitterlinden AG. Homocysteine and fracture prevention. JAMA 2005;293(9):1121-1122.
- van Rooij IA, Vermeij-Keers C, Kluijtmans LA, et al. Does the interaction between maternal folate intake and the methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or without cleft palate? Am J Epidemiol 2003;157(7):583-591.
- Varela-Moreiras G. Nutritional regulation of homocysteine: effects of drugs. Biomed Pharmacother 2001;55(8):448-453. (Review)
- Vaughn JD, Bailey LB, Shelton KP, et al. Methionine synthase reductase 66A→G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C→T variant. J Nutr 2004;134(11):2985-2990.
- Velzing-Aarts FV, Holm PI, Fokkema MR, et al. Plasma choline and betaine and their relation to plasma homocysteine in normal pregnancy. Am J Clin Nutr 2005;81:1383-1389.
- Venn BJ, Green TJ, Moser R, et al. Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study. Am J Clin Nutr 2003;77(3):658-662.
- Venn BJ, Mann JI, Williams SM, et al. Dietary counseling to increase natural folate intake: a randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine. Am J Clin Nutr 2002;76(4):758-765.
- Venn BJ, Mann JI, Williams SM, et al. Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial. Eur J Clin Nutr 2002;56(8):748-754.
- Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22(1):6-13. (Review)
- Verhaar MC, Wever RM, Kastelein JJ, et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia: a randomized placebo-controlled trial. Circulation 1999;100:335-338.
- Velzing-Aarts FV, Holm PI, Fokkema MR, et al. Plasma choline and betaine and their relation to plasma homocysteine in normal pregnancy. Am J Clin Nutr 2005;81:1383-1389.
- Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355(9203):517-522.
- Villareal DT, Miller BV III, Banks M, et al. Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am J Clin Nutr 2006;84:1317-1323.
- Virgos C, Martorell L, Simo JM, et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport 1999;10:2035-2038.
- Voutilainen S, Lakka TA, Porkkala-Sarataho E, et al. Low serum folate concentrations are associated with an excess incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr 2000;54:424-428.

## Citations and Reference Literature: Folic Acid

- Voutilainen S, Rissanen TH, Virtanen J, et al. Low dietary folate intake is associated with an excess incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. *Circulation* 2001;103(22):2674-2680.
- Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. *Arch Intern Med* 2001;161:695-700.
- Wald DS, Wald NJ, Morris JK, et al. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *BMJ* 2006;333(7578):1114-1117. (Editorial; Review)
- Wald NJ, Bower C. Folic acid, pernicious anaemia, and prevention of neural tube defects. *Lancet* 1994;343(8893):307.
- Wald NJ, Law MR, Morris JK, et al. Quantifying the effect of folic acid. *Lancet* 2001;358(9298):2069-2073. (Review) Erratum in *Lancet* 2002;359(9306):630.
- Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischaemic heart disease: results of a prospective study with implications on prevention. *Arch Intern Med* 1998;158:862-867.
- Walters T. Congenital megaloblastic anemia responsive to N5-formyl tetrahydrofolic acid administration. *J Pediatr* 1967;70:686-687.
- Wang HX, Wahlin A, Basun H, et al. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. *Neurology* 2001;56(9):1188-1194.
- Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 2006;355(25):2631-2639.
- Ward M, McNulty H, McPartlin J. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. *QJM* 1997;90:519-524.
- Ware JH. The limitations of risk factors as diagnostic tools. *N Engl J Med* 2006;355(25):2615-2617. (Editorial)
- Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. *Biochim Biophys Acta* 2003;2:99-111.
- Wedge SR, Laohavijit S, Taylor GA, et al. Clinical pharmacokinetics of the antipurine antifolate (6R)-5, 10-dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. *Clin Cancer Res* 1995;1(12):1479-1486.
- Weir DG, Molloy AM. Microvascular disease and dementia in the elderly: are they related to hyperhomocysteinemia? *Am J Clin Nutr* 2000;71(4):859-860.
- Weir DG, Scott JM. Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications. *Nutr Rev* 1998;11:311-338.
- Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol Genet Metab* 1998;64:169-172.
- Welch GN, Upchurch GR Jr, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. *Hosp Pract (Minneapolis)* 1997;32(6):81-82, 85, 88-92. (Review)
- Weller MM, Shapiro S, Mitchell AA, et al. Periconceptual folic acid exposure and risk of occurrent neural tube defects. *JAMA* 1993;269:1257-1261.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press; 1997:55-57. (Review)
- Werler MM, Hayes C, Louik C, et al. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol* 1999;150:675-682.
- Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. *JAMA* 1993;269:1257-1261.
- West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. *Gut* 1975;16:93-98.
- White E, Shannon JS, Patterson RE. Relationship between vitamin and calcium supplement use and colon cancer. *Cancer Epidemiol Biomarkers Prev* 1997;6:769-774.
- Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. *Rheumatology* 2004;43(3):267-271. (Review)
- Wiernsperger N. Metformin: intrinsic vasculoprotective properties. *Diabetes Technol Ther* 2000;2:259-272.
- Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. *Health Technol Assess* 2005;9(15):1-832.
- Willems FF, Boers GH, Blom HJ, et al. Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. *Br J Pharmacol* 2004;141(5):825-830.
- Williams C, Kingwell BA, Burke K, et al. Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype. *Am J Clin Nutr* 2005;82:26-31.
- Wilmink HW, Stroes ESG, Erkelens WD, et al. Influence of folic acid on postprandial endothelial dysfunction. *Arterioscler Thromb Vasc Biol* 2000;20:185-188.
- Winkelmayer WC, Huber A, Wagner OF, et al. Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients. *Kidney Int* 2005;67(5):1980-1985.

## Citations and Reference Literature: Folic Acid

- Wlodarczyk BJ, Cabrera RM, Hill DS, et al. Arsenic-induced gene expression changes in the neural tube of folate transport defective mouse embryos. *Neurotoxicology* 2006;27(4):547-557.
- Wolfe JM, Bailey LB, Herrlinger-Garcia K, et al. Folate catabolite excretion is responsive to changes in dietary folate intake in elderly women. *Am J Clin Nutr* 2003;77(4):919-923.
- Wong A, Mok V, Fan YH, et al. Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. *J Neurol* 2006;253(4):441-447.
- Woo KS, Chook P, Chan LL, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. *Am J Med* 2002;112(7):535-539.
- Woo KS, Chook P, Lolin YI, et al. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. *J Am Coll Cardiol* 1999;34(7):2002-2006.
- Wynn V. Vitamins and oral contraceptive use. *Lancet* 1975;1(7906):561-564.
- Xu XY, Zhou WH, Xiao CS, et al. [A clinical study of hyperhomocysteinemia in rheumatological diseases.] *Zhonghua Nei Ke Za Zhi* 2005;44(2):111-114. [Chinese]
- Yang TL, Hung J, Caudill MA, et al. A long-term controlled folate feeding study in young women supports the validity of the 1.7 multiplier in the dietary folate equivalency equation. *J Nutr* 2005;135(5):1139-1145.
- Yerby MS. Problems and management of the pregnant woman with epilepsy. *Epilepsia* 1987;28(Suppl 3):S29-36. (Review)
- Young SN, Ghadirian AM. Folic acid and psychopathology. *Prog Neuropsychopharmacol Biol Psychiatry* 1989;13(6):841-863. (Review)
- Yxfeldt A, Wallberg-Jonsson S, Hultdin J, et al. Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. *Scand J Rheumatol* 2003;32(4):205-210.
- Zarcone R, Bellini P, Carfora E, et al. [Folic acid and cervix dysplasia.] *Minerva Ginecol* 1996;48(10):397-400. [Italian]
- Zeller JL, Burke AE, Glass RM. Folic acid. *JAMA* 2006;296:2758.
- Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. *JAMA* 1999;281(17):1632-1637.
- Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. *Biochem Pharmacol* 2001;61(7):857-865.
- Zhu H, Yang W, Lu W, et al. A known functional polymorphism (Ile120Val) of the human PCMT1 gene and risk of spina bifida. *Mol Genet Metab* 2006;87(1):66-70.
- Zittoun J. Congenital errors of folate metabolism. *Baillieres Clin Haematol* 1995;8:603-616.
- Zlotogora J, Amitai Y, Leventhal A. Surveillance of neural tube defects in Israel: the effect of the recommendation for periconceptional folic acid. *Isr Med Assoc J* 2006;8(9):601-604.
- Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in l-dopa-treated Parkinson's disease patients with cognitive dysfunctions. *Clin Chem Lab Med* 2005;43(10):1107-1110.